{ "company": "Guardant Health", "ticker": "GH", "period": { "from": "2026-03-12", "to": "2026-04-11", "days": 30 }, "sentiment_breakdown": { "positive": 75, "negative": 63, "neutral": 62 }, "synthesis": { "executive_summary": "Sentiment analysis for Guardant Health (GH) from 2026-03-12 to 2026-04-11. Analyzed 200 items across FDA and news sources.", "key_findings": [], "overall_sentiment": "neutral" }, "top_positive": [ { "title": "Guardant Health gets oncology innovation accolade at Healthcare Asia Medtech Awards 2026", "date": "2026-04-01", "source": "alpha_vantage", "score": 0.881 }, { "title": "Heath Goldfields Has Brought Renewed Hope To Prestea-Bogoso -Group", "date": "2026-03-31", "source": "news", "score": 0.844 }, { "title": "Molecular Tumor Board Solutions Market Outlook 2026-2030 & 2035 with Competitor Market Share Data", "date": "2026-04-07", "source": "news", "score": 0.832 }, { "title": "Determination of factors that allow cryogenic nanoscopy with high power illumination without devitrification", "date": "2026-03-31", "source": "news", "score": 0.832 }, { "title": "Donors cheer up SHS Arts students for decorating Asokwa Interchange", "date": "2026-03-30", "source": "news", "score": 0.827 }, { "title": "5 popular OpenClaw integrations that will level up your productivity", "date": "2026-04-02", "source": "news", "score": 0.822 }, { "title": "Effects of a native avian predator (weka; Gallirallus australis) and colony density on breeding success of a burrow-nesting seabird (tītī; Ardenna grisea)", "date": "2026-04-02", "source": "news", "score": 0.802 }, { "title": "Show HN: Infer – Pipe friendly Agent Harness with one tool: Bash", "date": "2026-04-08", "source": "news", "score": 0.796 }, { "title": "Deliver Value For Money Or Face Sanctions – GETFund Boss Warns Contractors", "date": "2026-04-07", "source": "news", "score": 0.784 }, { "title": "Aura Reports Updated Mineral Reserves and Mineral Resources For The Year-Ended 2025, Highlighting year of Significant Growth in Mineral Reserve and Resource Portfolio", "date": "2026-04-01", "source": "news", "score": 0.778 } ], "top_negative": [ { "title": "Loss of luminal lineage drives resistance to next-generation ERα antagonists in pretreated ER(+) HER2(-) locally-advanced or metastatic breast cancer.", "date": "2026 Apr 1", "source": "pubmed", "score": -1.0 }, { "title": "Police Gun Down Suspected Armed Robber on Atebubu–Ejura Highway", "date": "2026-03-30", "source": "news", "score": -0.95 }, { "title": "Nsein chief gives Lower Axim counter three-month ultimatum to vacate his land", "date": "2026-04-01", "source": "news", "score": -0.905 }, { "title": "Biobanking of gynecologic cancer biospecimens: Development, quality control, and translational applications", "date": "2026-03-31", "source": "news", "score": -0.869 }, { "title": "Consensus definition of stage III non-small-cell lung cancer technical resectability to standardise inclusion criteria for clinical trials: a multisocietal EORTC-Lung Cancer Group collaboration.", "date": "2026 Mar 2", "source": "pubmed", "score": -0.869 }, { "title": "Global Noninvasive Cancer Diagnostics Market to Reach $165.2 Billion by 2030 as Liquid Biopsy, AI-Enabled Screening and Multi-Cancer Detection Tests Transform Oncology", "date": "2026-04-09", "source": "news", "score": -0.823 }, { "title": "Utility of Circulating Tumor DNA-Based Liquid Biopsies in Patients with Cancer Receiving Immunotherapy.", "date": "2026-04-11", "source": "pubmed", "score": -0.791 }, { "title": "Show HN: BAREmail ʕ·ᴥ·ʔ – minimalist Gmail client for bad WiFi", "date": "2026-04-08", "source": "news", "score": -0.758 }, { "title": "Real-world analysis of androgen receptor inhibitors in US patients with nonmetastatic castration-resistant prostate cancer: DEAR-EXT study.", "date": "2026 Mar 1", "source": "pubmed", "score": -0.751 }, { "title": "Dispatch Rider Jailed 10 Years for Robbing Diplomat’s Secretary", "date": "2026-04-03", "source": "news", "score": -0.727 } ], "raw_data": { "total_items": 200, "items": [ { "source": "alpha_vantage", "title": "Guardant Health Inc (GH) Stock Price Down 4.62% on Apr 9", "url": "https://www.gurufocus.com/news/8785466/guardant-health-inc-gh-stock-price-down-462-on-apr-9?mobile=true", "date": "2026-04-09", "summary": "Guardant Health Inc (GH) stock fell 4.62% on April 9th, reaching an intraday low of $88.22 before closing slightly higher at $88.61. This places the stock significantly above its 52-week low but still below its 52-week high. Wall Street analysts provide an average target price of $129.67, suggesting a 46.35% upside, with an \"Outperform\" consensus, while GuruFocus' estimated GF Value indicates a potential downside of 22.65% from the current price.", "sentiment_score": -0.390621, "sentiment_label": "Bearish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Guardant Health (GH) Chief People Officer sells 3,832 shares in open market", "url": "https://www.stocktitan.net/sec-filings/GH/form-4-guardant-health-inc-insider-trading-activity-32117b2b4a92.html", "date": "2026-04-08", "summary": "Guardant Health's Chief People Officer, Terilyn J. Monroe, sold 3,832 shares of common stock at $92.68 per share in an open-market transaction. Following this sale, Monroe still directly holds 20,990 shares of the company. This insider transaction was reported in a Form 4 filing, indicating a moderate impact and negative sentiment.", "sentiment_score": -0.236019, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Citi Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $150", "url": "https://www.moomoo.com/news/post/67968522/citi-maintains-guardant-health-ghus-with-buy-rating-maintains-target", "date": "2026-04-08", "summary": "Citi has reiterated its Buy rating for Guardant Health (GH.US), maintaining a target price of $150. This continued endorsement suggests confidence in the company's future performance and valuation. The specific reasons for Citi's reiterated stance were not detailed in the provided content.", "sentiment_score": 0.465834, "sentiment_label": "Bullish", "relevance_score": 0.997937, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Should Guardant Health’s (GH) Role in ENHERTU’s Japan Approval Require Action From Investors?", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/should-guardant-healths-gh-role-in-enhertus-japan-approval-r/amp", "date": "2026-04-08", "summary": "Guardant Health's InfinityAI platform was instrumental in the Japanese approval of Daiichi Sankyo's ENHERTU, a development that could enhance Guardant's standing in biopharma and data partnerships. While this strengthens the investment narrative around its AI and real-world evidence capabilities, the company still faces significant challenges, including ongoing losses, high spending, and potential future dilution. Investors are encouraged to weigh this positive news against the risks of negative", "sentiment_score": 0.121955, "sentiment_label": "Neutral", "relevance_score": 0.955442, "sentiment": { "label": "positive", "score": 0.477, "confidence": 0.48 } }, { "source": "alpha_vantage", "title": "Should Guardant Health’s (GH) Role in ENHERTU’s Japan Approval Require Action From Investors?", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/should-guardant-healths-gh-role-in-enhertus-japan-approval-r", "date": "2026-04-08", "summary": "Guardant Health's InfinityAI platform was instrumental in obtaining Japan's approval for Daiichi Sankyo's ENHERTU, showcasing its potential in leveraging clinicogenomic data and AI for regulatory assessments. While this strengthens Guardant's position in the biopharma and data sectors, the article emphasizes that the core investment risks remain centered on high spending, negative free cash flow, and potential future dilution. Investors should consider the company's long-term financial health an", "sentiment_score": 0.198089, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.986163, "sentiment": { "label": "positive", "score": 0.477, "confidence": 0.48 } }, { "source": "alpha_vantage", "title": "Insider Sell: Terilyn Monroe Sells Shares of Guardant Health Inc (GH)", "url": "https://www.gurufocus.com/news/8780017/insider-sell-terilyn-monroe-sells-shares-of-guardant-health-inc-gh", "date": "2026-04-08", "summary": "Terilyn Monroe, Chief People Officer at Guardant Health Inc (GH), sold 3,832 shares of the company on April 6, 2026. This transaction follows a pattern of 45 insider sells and no buys over the past year. Guardant Health Inc's stock is currently trading at $92.68, which is significantly overvalued compared to its GF Value of $53.19.", "sentiment_score": -0.438045, "sentiment_label": "Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Guardant Health Insider Sells $355K in Shares", "url": "https://nationaltoday.com/us/ca/redwood-city/news/2026/04/07/guardant-health-insider-sells-355k-in-shares/", "date": "2026-04-07", "summary": "A Guardant Health insider, Terilyn Monroe, recently sold 3,832 shares of the company's stock for over $355,000. This transaction, executed under a pre-arranged trading plan, has raised questions about the company's future prospects. While the sale could signal potential concerns, the use of a Rule 10b5-1 plan aims to prevent allegations of insider trading.", "sentiment_score": -0.297347, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Guardant Health (GH) chief people officer sells $355k in stock", "url": "https://www.investing.com/news/insider-trading-news/guardant-health-gh-chief-people-officer-sells-355k-in-stock-93CH-4601762", "date": "2026-04-07", "summary": "Guardant Health's Chief People Officer, Terilyn J. Monroe, sold 3,832 shares of common stock for approximately $355,149. This transaction occurred after a significant 123% stock gain over the past year, though the stock is currently considered overvalued by InvestingPro analysis. The article also touches on recent company news, including strong Q4 2025 results and positive analyst ratings.", "sentiment_score": 0.132338, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Canaccord reiterates Guardant Health stock rating on cancer test growth", "url": "https://www.investing.com/news/analyst-ratings/canaccord-reiterates-guardant-health-stock-rating-on-cancer-test-growth-93CH-4600161", "date": "2026-04-07", "summary": "Canaccord Genuity reiterated a Buy rating and $135 price target for Guardant Health (NASDAQ:GH), citing the strong performance and growth potential of the company's cancer screening initiatives, particularly the Shield test. Despite the stock's significant return over the past year, InvestingPro analysis indicates it trades above its fair value. Guardant Health's Shield test has exceeded historical benchmarks for screening and diagnostic test launches, with expectations of 150% year-over-year te", "sentiment_score": 0.700321, "sentiment_label": "Bullish", "relevance_score": 0.95096, "sentiment": { "label": "negative", "score": -0.421, "confidence": 0.42 } }, { "source": "alpha_vantage", "title": "Guardant Health, Organon, Fortrea, QuidelOrtho, and Charles River Laboratories Stocks Trade Down, What You Need To Know", "url": "https://www.tradingview.com/news/stockstory:39a9d653b094b:0-guardant-health-organon-fortrea-quidelortho-and-charles-river-laboratories-stocks-trade-down-what-you-need-to-know/", "date": "2026-04-06", "summary": "Shares of several health-related companies, including Guardant Health, Organon, Fortrea, QuidelOrtho, and Charles River Laboratories, experienced declines after a proposed 2027 federal budget revealed significant spending cuts for key health agencies like the Department of Health and Human Services and the National Institutes of Health. While Congress is unlikely to approve the full extent of the cuts, the proposal introduced uncertainty for the sector, causing immediate stock drops. QuidelOrtho", "sentiment_score": -0.308439, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "[144] Guardant Health, Inc. SEC Filing", "url": "https://www.stocktitan.net/sec-filings/GH/144-guardant-health-inc-sec-filing-5a5dabd6720a.html", "date": "2026-04-06", "summary": "Guardant Health, Inc. (GH) has filed a Form 144 with the SEC, indicating proposed sales of common stock. This filing details a future sale of 3,832 shares through Charles Schwab & Co. on April 1, 2026, stemming from a restricted stock lapse. It also discloses two past sales by Terilyn J. Monroe on January 7, 2026, and January 21, 2026, totaling 18,602 shares.", "sentiment_score": 0.011923, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Guardant Health, Inc. $GH is Capricorn Fund Managers Ltd's 6th Largest Position", "url": "https://www.marketbeat.com/instant-alerts/filing-guardant-health-inc-gh-is-capricorn-fund-managers-ltds-6th-largest-position-2026-04-06/", "date": "2026-04-06", "summary": "Capricorn Fund Managers Ltd significantly increased its stake in Guardant Health (GH) by 197.8% in Q4, making it their 6th largest holding. Despite missing EPS estimates, Guardant Health's Q4 revenue beat expectations, leading several analysts to raise their price targets. The stock has a \"Moderate Buy\" consensus rating, high institutional ownership, but also saw insider selling.", "sentiment_score": 0.256777, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Guardant Health (GH) Valuation After Japan ENHERTU Approval Backed By InfinityAI Real World Evidence", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/guardant-health-gh-valuation-after-japan-enhertu-approval-ba", "date": "2026-04-04", "summary": "Guardant Health (GH) is in focus after Japan approved ENHERTU for certain HER2 positive cancers, partly supported by Guardant's InfinityAI platform. Despite a 131.22% one-year return, the stock has seen a recent decline, prompting questions about its valuation. While a narrative suggests a 28.2% undervaluation with a fair value of $130.64 due to AI integration and expanded clinical applications, a sales multiple analysis indicates the stock might appear rich compared to the broader healthcare se", "sentiment_score": 0.345635, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.494, "confidence": 0.49 } }, { "source": "alpha_vantage", "title": "Guardant Health (GH) CPO gains stock from RSU vesting and tax withholding", "url": "https://www.stocktitan.net/sec-filings/GH/form-4-guardant-health-inc-insider-trading-activity-56ee3da8ffc2.html", "date": "2026-04-03", "summary": "Guardant Health's Chief People Officer, Terilyn J. Monroe, received 8,019 shares of common stock on April 1, 2026, due to the vesting of restricted stock units. Subsequently, 4,187 shares were withheld by the company at $91.15 per share to cover tax obligations. After these transactions, Monroe directly holds 24,822 shares of Guardant Health common stock, reflecting routine equity compensation rather than open-market trading.", "sentiment_score": 0.04713, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.34, "confidence": 0.34 } }, { "source": "alpha_vantage", "title": "Guardant Health (GH) CMO nets shares as RSUs vest and taxes withheld", "url": "https://www.stocktitan.net/sec-filings/GH/form-4-guardant-health-inc-insider-trading-activity-962fc1dbb93d.html", "date": "2026-04-02", "summary": "Guardant Health's Chief Medical Officer, Craig Eagle, acquired 11,400 shares of common stock through the vesting of Restricted Stock Units (RSUs) on April 1, 2026. As part of this process, 5,779 shares were withheld by the company to cover tax obligations. Following these transactions, Eagle directly holds 72,001 shares of Guardant Health common stock.", "sentiment_score": 0.02, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Guardant Health (GH) co-CEO reports RSU vesting, tax-share withholdings and over 2.1M shares held", "url": "https://www.stocktitan.net/sec-filings/GH/form-4-guardant-health-inc-insider-trading-activity-87afe3f0262c.html", "date": "2026-04-02", "summary": "Guardant Health's co-CEO, Helmy Eltoukhy, reported routine equity compensation activity involving Restricted Stock Units (RSUs) that vested on March 31 and April 1, 2026. These transactions resulted in the conversion of tens of thousands of RSUs into common stock, with shares withheld by the company to cover tax obligations. Following these events, Eltoukhy, through a revocable trust, holds over 2.1 million shares of common stock, in addition to directly holding 68,011 restricted stock units.", "sentiment_score": 0.044145, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "11,213 Guardant Health (GH) RSUs vest; 4,750 shares withheld for tax", "url": "https://www.stocktitan.net/sec-filings/GH/form-4-guardant-health-inc-insider-trading-activity-7025cfabc0b9.html", "date": "2026-04-02", "summary": "Guardant Health's Chief Commercial Officer, Chris Freeman, had 11,213 Restricted Stock Units (RSUs) vest on April 1, 2026. To cover tax obligations, 4,750 shares were withheld by the company at a price of $91.15 per share. Following these transactions, Freeman directly held 60,034 shares of Guardant Health common stock.", "sentiment_score": 0.031282, "sentiment_label": "Neutral", "relevance_score": 0.959077, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "SWS Partners Has $7.89 Million Holdings in Guardant Health, Inc. $GH", "url": "https://www.marketbeat.com/instant-alerts/filing-sws-partners-has-789-million-holdings-in-guardant-health-inc-gh-2026-04-02/", "date": "2026-04-02", "summary": "SWS Partners reduced its stake in Guardant Health (NASDAQ:GH) by 18.3% in the fourth quarter, holding 77,209 shares valued at $7.89 million, representing 1.5% of its portfolio. Guardant Health reported Q4 EPS of -$0.50, missing estimates, but revenue increased by 39.4% to $281.3 million. Analysts have a \"Moderate Buy\" consensus rating with an average target price of $125.95, despite recent insider selling totaling $2.51 million.", "sentiment_score": 0.060469, "sentiment_label": "Neutral", "relevance_score": 0.971122, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Allspring Global Investments Holdings LLC Reduces Stock Holdings in Guardant Health, Inc. $GH", "url": "https://www.marketbeat.com/instant-alerts/filing-allspring-global-investments-holdings-llc-reduces-stock-holdings-in-guardant-health-inc-gh-2026-04-02/", "date": "2026-04-02", "summary": "Allspring Global Investments Holdings LLC significantly reduced its stake in Guardant Health, Inc. (NASDAQ:GH) by 1.9% in the fourth quarter, selling 12,256 shares and now owning 618,599 shares valued at $62.94 million. Insider transactions also show sales of 23,250 shares totaling $2.51 million in the last 90 days. Despite these reductions, analysts maintain a \"Moderate Buy\" rating with an average price target of $125.95 for Guardant Health, a precision oncology company.", "sentiment_score": 0.129094, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Guardant Health Stock Rises on Japan Regulatory News for Daiichi Sankyo Drug - News and Statistics", "url": "https://www.indexbox.io/blog/guardant-health-stock-gains-on-japan-drug-approval-using-infinityai-data/", "date": "2026-04-02", "summary": "Guardant Health's stock saw a significant increase following the approval of a cancer drug by Daiichi Sankyo in Japan, which utilized real-world evidence from Guardant's InfinityAI platform. This event highlights the growing role of AI and real-world data in regulatory decisions for new treatments, despite the historical volatility of Guardant Health's stock. The article also includes extensive information about an antisera industry report for Japan, unrelated to the main news.", "sentiment_score": 0.345892, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Guardant Health (NasdaqGS:GH) Stock Forecast & Analyst Predictions", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/future", "date": "2026-04-02", "summary": "Guardant Health (NasdaqGS:GH) is forecasted to experience significant growth, with earnings projected to increase by 55.1% and revenue by 20.9% annually. Despite being unprofitable for the next three years, its revenue growth is expected to outpace the US market. Analysts have also recently increased its price target, signaling positive sentiment for the company's future performance.", "sentiment_score": 0.393861, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Director at Guardant Health (GH) acquires 155 shares via RSUs", "url": "https://www.stocktitan.net/sec-filings/GH/form-4-guardant-health-inc-insider-trading-activity-0a86624789a6.html", "date": "2026-04-01", "summary": "Guardant Health director Steve E. Krognes acquired 155 shares of Common Stock by exercising Restricted Stock Units. This transaction on March 31, 2026, was a routine equity-compensation event at an exercise price of $0.00 per share. Following this, Krognes' direct holdings in Common Stock increased to 19,208 shares, and he retains 463 Restricted Stock Units.", "sentiment_score": 0.041456, "sentiment_label": "Neutral", "relevance_score": 0.335289, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Guardant Health gets oncology innovation accolade at Healthcare Asia Medtech Awards 2026", "url": "https://mugglehead.com/guardant-health-gets-oncology-innovation-accolade-at-healthcare-asia-medtech-awards-2026/", "date": "2026-04-01", "summary": "Guardant Health Inc. (NASDAQ: GH) (FRA: 5GH) received the Oncology Product Innovation of the Year award at the Healthcare Asia Medtech Awards 2026 for its Shield multi-cancer detection test. The award comes shortly after Guardant launched Shield in Hong Kong, Singapore, and the Philippines, partnering with Manulife to offer the test to insurance customers. The Shield test, a methylation-based blood test, screens for 10 common cancers with high specificity, improving early detection and patient o", "sentiment_score": 0.420724, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.881, "confidence": 0.88 } }, { "source": "alpha_vantage", "title": "Guardant Health (GH) and Verana Health Announces New Partnership", "url": "https://www.insidermonkey.com/blog/guardant-health-gh-and-verana-health-announces-new-partnership-1727963/?amp=1", "date": "2026-03-31", "summary": "Guardant Health (NASDAQ:GH) and Verana Health have announced a new partnership to provide biopharmaceutical researchers with access to Guardant's clinicogenomic testing data and Verana's EHR datasets. This collaboration aims to accelerate the development of new therapies and improve patient care by allowing researchers to connect molecular biomarkers with treatment decisions and clinical outcomes. Guardant Health specializes in precision oncology, using data, blood-based tests, and advanced anal", "sentiment_score": 0.401398, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.2, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "Why Is Guardant Health (GH) Stock Soaring Today", "url": "https://www.tradingview.com/news/stockstory:4270c6473094b:0-why-is-guardant-health-gh-stock-soaring-today/", "date": "2026-03-31", "summary": "Guardant Health (GH) stock saw a 5.9% increase after the company announced that its InfinityAI platform's real-world evidence contributed to the approval of the cancer drug ENHERTU® in Japan. This development validates Guardant's AI technology in precision oncology. Despite the recent jump, the stock remains volatile and is down 9.2% year-to-date and 21.2% below its 52-week high.", "sentiment_score": 0.023271, "sentiment_label": "Neutral", "relevance_score": 0.312099, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Guardant Health real-world data supports Japan approval of ENHERTU for HER2-positive tumors", "url": "https://www.msn.com/en-us/health/other/guardant-health-real-world-data-supports-japan-approval-of-enhertu-for-her2-positive-tumors/ar-AA1ZJdPW?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "date": "2026-03-31", "summary": "Guardant Health's real-world data has supported the Japan Pharmaceuticals and Medical Devices Agency's approval of ENHERTU for treating HER2-positive tumors. This approval represents a significant step forward in personalized medicine for these cancer types, leveraging genomic profiling for treatment decisions. The data likely demonstrated the effectiveness or necessity of identifying HER2 status in patients.", "sentiment_score": 0.616812, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.681, "confidence": 0.68 } }, { "source": "alpha_vantage", "title": "The Bull Case For Guardant Health (GH) Could Change Following Japan’s ENHERTU Approval Using Its AI Data", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/the-bull-case-for-guardant-health-gh-could-change-following", "date": "2026-03-31", "summary": "Guardant Health's InfinityAI and Guardant360 platforms helped secure regulatory approval for Daiichi Sankyo’s ENHERTU in Japan, demonstrating the growing role of AI-driven real-world data in oncology drug approvals. While this reinforces the value of Guardant's data assets, the company still faces challenges with cash burn and achieving profitability. The approval, alongside partnerships like Verana Health, solidifies Guardant's position in AI-enabled oncology data but raises execution risks in ", "sentiment_score": 0.309452, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.477, "confidence": 0.48 } }, { "source": "alpha_vantage", "title": "Guardant Health Inc (GH) Trading Down 3.96% on Mar 30", "url": "https://www.gurufocus.com/news/8756885/guardant-health-inc-gh-trading-down-396-on-mar-30?mobile=true", "date": "2026-03-30", "summary": "Guardant Health Inc (GH) experienced a 3.96% decline in its stock price on March 30, trading down to $84.61. While Wall Street analysts have an average target price of $129.67, suggesting a potential upside, GuruFocus estimates a different fair value of $67.08, implying a downside from the current price. The stock's trading volume was significantly higher than its average daily volume during this period.", "sentiment_score": -0.258931, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Guardant Health’s InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan", "url": "https://www.businesswire.com/news/home/20260330846159/en/Guardant-Healths-InfinityAI-Real-World-Evidence-Supports-Approval-of-ENHERTU-for-Previously-Treated-Patients-with-HER2-Positive-Metastatic-Solid-Tumors-in-Japan", "date": "2026-03-30", "summary": "Guardant Health's InfinityAI platform provided crucial real-world evidence, alongside clinical trial data, to support the recent approval of ENHERTU® in Japan. This approval, granted by Japan’s Ministry of Health, Labour and Welfare, is for treating HER2-positive metastatic solid cancers refractory to standard treatments. The collaboration with Daiichi Sankyo highlights the increasing importance of real-world data in expanding access to targeted therapies for rare biomarker-defined patient popul", "sentiment_score": 0.469191, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.735, "confidence": 0.74 } }, { "source": "alpha_vantage", "title": "Guardant Health to present new cancer research while stock trades lower amid strong sell signals", "url": "https://tradersunion.com/news/companies/show/1818093-guardant-health-drops-3-96percent-today/", "date": "2026-03-29", "summary": "Guardant Health is set to present 28 abstracts at the AACR26 event, showcasing advancements in cancer diagnostics and research, particularly in methylation-based tumor classification and multiomic testing. Despite this upcoming presentation of new cancer research, the company's stock has experienced a 3.96% intraday drop, trading lower amid strong sell signals and sustained bearish momentum. Technical indicators suggest further downside risk, with the stock positioned below key moving averages a", "sentiment_score": -0.643947, "sentiment_label": "Bearish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.511, "confidence": 0.51 } }, { "source": "alpha_vantage", "title": "Guardant Health Shares Fall as Market Reacts to Conflict, Policy Deadlines | 2026 - News and Statistics", "url": "https://www.indexbox.io/blog/guardant-health-stock-drops-amid-market-uncertainty-and-low-consumer-confidence/", "date": "2026-03-28", "summary": "Guardant Health's stock declined in afternoon trading, reflecting broader market unease fueled by international conflict and upcoming policy deadlines. This market sentiment also pushed consumer confidence to a three-month low, and the company's shares are now trading below their year-to-date peak and are worth less than their value five years ago. The article also provides details on a report about the composite laboratory reagents industry in the United States, including market analysis, trade", "sentiment_score": -0.643509, "sentiment_label": "Bearish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": -0.026, "confidence": 0.03 } }, { "source": "alpha_vantage", "title": "Why Guardant Health (GH) Stock Is Falling Today", "url": "https://www.tradingview.com/news/stockstory:a4995f8d7094b:0-why-guardant-health-gh-stock-is-falling-today/", "date": "2026-03-27", "summary": "Guardant Health (GH) stock fell 3% today due to escalating uncertainty from the U.S.-Iran conflict and Trump administration policy deadlines, which also caused major indices to drop. This follows a 3.4% dip almost a month ago driven by higher-than-expected wholesale inflation data. Guardant Health's shares are highly volatile and have fallen 16.7% year-to-date, trading significantly below its 52-week high.", "sentiment_score": -0.418814, "sentiment_label": "Bearish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.153, "confidence": 0.15 } }, { "source": "alpha_vantage", "title": "Guardant Health wins at Healthcare Asia Medtech Awards 2026", "url": "https://healthcareasiamagazine.com/co-written-partner/event-news/guardant-health-wins-healthcare-asia-medtech-awards-2026", "date": "2026-03-27", "summary": "Guardant Health Pte Ltd won the Oncology Product Innovation of the Year at the Healthcare Asia Medtech Awards 2026 for its ShieldTM Multi-cancer Detection (MCD) test. This blood test screens for 10 types of cancers, demonstrating 99% overall specificity and 74% sensitivity across six aggressive cancers in recent data. The Shield MCD test has also received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA).", "sentiment_score": 0.401755, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.772, "confidence": 0.77 } }, { "source": "alpha_vantage", "title": "Tempus AI Reinforces Market Position With Collaborations in 2026", "url": "https://www.tradingview.com/news/zacks:5e5cf70e2094b:0-tempus-ai-reinforces-market-position-with-collaborations-in-2026/", "date": "2026-03-26", "summary": "Tempus AI (TEM) is strengthening its market position in 2026 through strategic collaborations with pharmaceutical companies, healthcare institutions, and technology innovators. These partnerships aim to improve clinical outcomes and accelerate drug development by leveraging Tempus's AI expertise and proprietary platforms. Notable collaborations include work with Daiichi Sankyo on an ADC program, Median Technologies for lung nodule characterization, Blood Cancer United for a pediatric AML registr", "sentiment_score": 0.035905, "sentiment_label": "Neutral", "relevance_score": 0.340085, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Guardant Health (GH) partners with Manulife to launch Shield multi-cancer detection test in Asia", "url": "http://www.msn.com/en-us/health/other/guardant-health-gh-partners-with-manulife-to-launch-shield-multi-cancer-detection-test-in-asia/ar-AA1Z4xZA?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "date": "2026-03-25", "summary": "Guardant Health (GH) is partnering with Manulife to introduce its Shield multi-cancer detection test across Asia. This collaboration aims to provide enhanced cancer screening options in the region, leveraging Manulife's network to expand access to Guardant Health's diagnostic technology. The initiative represents a significant step in making advanced multi-cancer detection more widely available.", "sentiment_score": 0.436892, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Guardant Health Ignites 5.6% Surge: A Volatile Breakout or a Trap for the Unwary?", "url": "https://www.bitget.com/news/detail/12560605304566", "date": "2026-03-25", "summary": "Guardant Health (GH) experienced a 5.63% intraday surge to $89.245, driven by a new partnership with Manulife, despite technical indicators like the RSI being deeply oversold. While the rally shows short-term bullish momentum and potential for breakout past the 30-day moving average, it faces resistance around the $90 psychological barrier and requires sustained movement above $95 to confirm a trend reversal. Options traders are targeting calls with high leverage and liquidity, signaling aggress", "sentiment_score": 0.321298, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.318, "confidence": 0.32 } }, { "source": "alpha_vantage", "title": "Cancer drug researchers gain combined patient and genomics data", "url": "https://www.stocktitan.net/news/GH/verana-health-and-guardant-health-partner-to-advance-precision-2sbofpkxcb3q.html", "date": "2026-03-24", "summary": "Verana Health and Guardant Health have partnered to combine Verana's EHR datasets with Guardant's clinicogenomic testing data, aiming to accelerate oncology drug development and enhance real-world treatment insights. This collaboration expands access to over 95 million patients and more than 30 academic medical centers, providing biopharmaceutical researchers with comprehensive data to understand patient journeys and validate molecular biomarkers. The partnership is expected to streamline drug d", "sentiment_score": 0.314968, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.981, "sentiment": { "label": "negative", "score": -0.25, "confidence": 0.25 } }, { "source": "alpha_vantage", "title": "Verana and Guardant’s RWE Stack Aims to Solve Precision Oncology’s Data Challenges—Driving Growth Through Recurring Revenue and Broader Data Collections", "url": "https://www.bitget.com/amp/news/detail/12560605299239", "date": "2026-03-24", "summary": "Verana Health and Guardant Health are collaborating to build a robust real-world evidence (RWE) data platform to address precision oncology's data challenges. This partnership integrates Guardant's clinicogenomic datasets with COTA's AI-enhanced oncology data, acquired through Verana's merger, to provide comprehensive insights for drug development. The strategy focuses on high-margin, recurring revenue streams from companion diagnostics and expanding into new therapeutic areas like bladder and p", "sentiment_score": 0.041436, "sentiment_label": "Neutral", "relevance_score": 0.305796, "sentiment": { "label": "positive", "score": 0.527, "confidence": 0.53 } }, { "source": "alpha_vantage", "title": "Verana Health and Guardant Health Partner to Advance Precision Medicine with Real-World Data", "url": "https://www.prnewswire.com/news-releases/verana-health-and-guardant-health-partner-to-advance-precision-medicine-with-real-world-data-302719285.html", "date": "2026-03-24", "summary": "Verana Health and Guardant Health have partnered to combine their real-world data resources to accelerate precision medicine, particularly in oncology and urology. This collaboration will allow biopharmaceutical researchers to access curated EHR data alongside clinicogenomic testing data, enhancing the understanding of patient journeys and aiding therapy development. The combined data sets will help validate correlations between molecular biomarkers, treatment decisions, and clinical outcomes, a", "sentiment_score": 0.410529, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Guardant Health (GH) director’s RSU vesting adds 264 common shares", "url": "https://www.stocktitan.net/sec-filings/GH/form-4-guardant-health-inc-insider-trading-activity-5b119b371c3f.html", "date": "2026-03-24", "summary": "Guardant Health director Roberto Mignone reported the vesting and settlement of 264 restricted stock units (RSUs) into common shares. This transaction, part of a routine equity compensation event, increased his direct holdings to 4,487 common shares and 8,184 RSUs. The vested RSUs are from an award granted on November 8, 2024, with a vesting schedule of 25% on the one-year anniversary and the remainder monthly over three years.", "sentiment_score": 0.013938, "sentiment_label": "Neutral", "relevance_score": 0.306583, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Guardant Health (GH) Valuation Check As New Manulife Partnership Expands Shield Testing In Asia", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/guardant-health-gh-valuation-check-as-new-manulife-partnersh", "date": "2026-03-23", "summary": "Guardant Health (GH) is under scrutiny after announcing a partnership with Manulife to expand its Shield multi-cancer detection blood test in Asia, starting April 2026. Despite recent share price volatility, the company has shown strong long-term momentum with an 84.77% one-year return, yet some models suggest it's significantly undervalued. The article debates whether the market has already factored in future growth, highlighting potential valuation risks from a high P/S ratio compared to the i", "sentiment_score": 0.261943, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.303, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Guardant Health (GH) partners with Manulife to launch Shield multi-cancer detection test in Asia", "url": "https://www.msn.com/en-us/health/other/guardant-health-gh-partners-with-manulife-to-launch-shield-multi-cancer-detection-test-in-asia/ar-AA1Z4xZA", "date": "2026-03-22", "summary": "Guardant Health (GH) has partnered with Manulife to introduce its Shield multi-cancer detection test in Asia. This collaboration aims to provide early cancer detection solutions to a broader population in the region through Manulife's network. The Shield test is designed to detect multiple types of cancer at early stages, potentially improving patient outcomes.", "sentiment_score": 0.405292, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Why Guardant Health’s (GH) 2026 screening story reinforced Piper Sandler’s bullish view", "url": "https://www.msn.com/en-us/money/companies/why-guardant-health-s-gh-2026-screening-story-reinforced-piper-sandler-s-bullish-view/ar-AA1YTUKn?ocid=finance-verthp-feeds", "date": "2026-03-21", "summary": "This article discusses Piper Sandler's maintained bullish outlook on Guardant Health (GH), specifically reinforced by insights from the company's 2026 screening strategy. The analyst firm highlighted a conference presentation that detailed key upcoming milestones and reiterated confidence in Guardant Health's future growth prospects.", "sentiment_score": 0.845381, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Guardant Health (GH) partners with Manulife to launch Shield multi-cancer detection test in Asia", "url": "https://www.msn.com/en-us/money/general/guardant-health-gh-partners-with-manulife-to-launch-shield-multi-cancer-detection-test-in-asia/ar-AA1Z4xZA", "date": "2026-03-21", "summary": "Guardant Health (GH) has partnered with Manulife to launch its Shield multi-cancer detection test in Asia. This collaboration aims to make the early cancer detection test accessible to a broader population in the region, leveraging Manulife's network. The Shield test is designed to detect multiple types of cancer from a single blood draw.", "sentiment_score": 0.412112, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Insider Sell: Musa Tariq Sells Shares of Guardant Health Inc (GH)", "url": "https://www.gurufocus.com/news/8728137/insider-sell-musa-tariq-sells-shares-of-guardant-health-inc-gh", "date": "2026-03-20", "summary": "Musa Tariq, a Director at Guardant Health Inc (GH), sold 348 shares of the company on March 18, 2026, bringing his total ownership to 8,394 shares. Over the past year, Tariq has sold a total of 4,489 shares with no purchases. Guardant Health Inc is considered significantly overvalued with a price-to-GF-Value ratio of 1.68, based on its trading price of $88.09 against a GF Value of $52.52.", "sentiment_score": -0.332954, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Insider Selling: Guardant Health (NASDAQ:GH) Director Sells 348 Shares of Stock", "url": "https://www.marketbeat.com/instant-alerts/insider-selling-guardant-health-nasdaqgh-director-sells-348-shares-of-stock-2026-03-19/", "date": "2026-03-19", "summary": "Guardant Health (NASDAQ:GH) Director Musa Tariq sold 348 shares of the company's stock on March 18, 2026, for a total value of $30,655.32. This sale reduced his stake by 3.98% to 8,394 shares. The company's stock traded up 2.1% to $89.08, and despite missing Q4 EPS estimates, revenue increased by 39.4% year-over-year.", "sentiment_score": -0.179836, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Guardant Health (NASDAQ: GH) director sells 348 company shares", "url": "https://www.stocktitan.net/sec-filings/GH/form-4-guardant-health-inc-insider-trading-activity-426fc16d4cb8.html", "date": "2026-03-19", "summary": "Guardant Health director Tariq Musa sold 348 shares of the company's common stock on March 18, 2026, at an average price of $88.09 per share. This open-market transaction was reported via a Form 4 SEC filing. Following the sale, Musa directly holds 8,394 shares of Guardant Health stock.", "sentiment_score": -0.259304, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Guardant Health (GH) director Tariq Musa sells $30,655 in stock", "url": "https://m.investing.com/news/insider-trading-news/guardant-health-gh-director-tariq-musa-sells-30655-in-stock-93CH-4571897?ampMode=1", "date": "2026-03-19", "summary": "Guardant Health (GH) director Tariq Musa sold 348 shares of common stock for $30,655 on March 18, 2026, bringing his total direct ownership to 8,394 shares. This insider sale occurs as the company's stock trades near $89.08. Separately, Guardant Health recently reported its Q4 2025 results, with several analysts reaffirming or increasing price targets due to strong performance and a positive outlook for commercial expansion and cost management.", "sentiment_score": 0.102698, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Cathie Wood’s ARK sells Guardant Health stock, buys Arcturus Therapeutics", "url": "https://www.investing.com/news/company-news/cathie-woods-ark-sells-guardant-health-stock-buys-arcturus-therapeutics-93CH-4569651", "date": "2026-03-19", "summary": "Cathie Wood's ARK sold 11,757 shares of Guardant Health (NASDAQ:GH) totaling over $1 million through its ARKG ETF, continuing a trend of reducing its position in the company. Concurrently, ARK purchased 33,864 shares of Arcturus Therapeutics Holdings (NASDAQ:ARCT) for $216,390, indicating a strategic shift towards innovative therapeutics. A smaller sale of Standard Biotools (NASDAQ:LAB) shares also occurred, reflecting ARK's ongoing portfolio reallocation within the biotech sector.", "sentiment_score": -0.410617, "sentiment_label": "Bearish", "relevance_score": 0.966737, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Director at Guardant Health (GH) receives 232 shares via RSUs", "url": "https://www.stocktitan.net/sec-filings/GH/form-4-guardant-health-inc-insider-trading-activity-5d6041acaa59.html", "date": "2026-03-18", "summary": "Guardant Health director Manuel Hidalgo Medina received 232 common shares through the exercise of restricted stock units (RSUs) on March 17, 2026, as part of his equity compensation. These shares were converted at a price of $0.00 per share, increasing his direct holdings to 1,425 shares. The RSU award originated from a grant on July 17, 2024, with a four-year vesting schedule.", "sentiment_score": 0.020196, "sentiment_label": "Neutral", "relevance_score": 0.335683, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "news", "source_name": "Luxurydaily.com", "title": "Singer Renée Rapp carries Stella McCartney’s Falabella bag forward", "description": "Seventeen years on, the British fashion house’s most beloved accessory finds a new spokesperson.", "url": "https://www.luxurydaily.com/singer-renee-rapp-carries-stella-mccartneys-falabella-bag-forward/", "date": "2026-04-10", "published_at": "2026-04-10T08:45:10Z", "sentiment": { "label": "positive", "score": 0.556, "confidence": 0.56 } }, { "source": "news", "source_name": "C-sharpcorner.com", "title": "Superpowers by obra: What It Is and How to Use It to Improve AI Coding", "description": "Superpowers by obra: A workflow-first approach to AI coding. Standardize skills for Claude, Cursor, Codex, and more. Improve AI coding habits with TDD and code review.", "url": "https://www.c-sharpcorner.com/article/superpowers-by-obra-what-it-is-and-how-to-use-it-to-improve-ai-coding/", "date": "2026-04-10", "published_at": "2026-04-10T04:32:14Z", "sentiment": { "label": "positive", "score": 0.726, "confidence": 0.73 } }, { "source": "news", "source_name": "ComingSoon.net", "title": "General Hospital’s Carly Actor Confirms Appearance in a New Movie", "description": "Laura Wright, who plays Carly Spencer in General Hospital, took to social media to confirm her role in an upcoming satire comedy movie. Introduced in 2005, Wright’s character is the daughter of John Durant and the late Nurse Bobbie Spencer in GH. The upcoming…", "url": "https://www.comingsoon.net/tv/news/2118455-general-hospital-carly-laura-wright-new-movie", "date": "2026-04-10", "published_at": "2026-04-10T04:16:38Z", "sentiment": { "label": "positive", "score": 0.542, "confidence": 0.54 } }, { "source": "news", "source_name": "David.coffee", "title": "I Still Prefer MCP over Skills", "description": "Why I believe the Model Context Protocol (MCP) is a better architectural pattern than the emerging “Skills” trend for LLM tool integration.", "url": "https://david.coffee/i-still-prefer-mcp-over-skills/", "date": "2026-04-10", "published_at": "2026-04-10T02:01:48Z", "sentiment": { "label": "positive", "score": 0.44, "confidence": 0.44 } }, { "source": "news", "source_name": "Pypi.org", "title": "gh-clean added to PyPI", "description": "Remote GitHub branch cleanup reporting tool", "url": "https://pypi.org/project/gh-clean/", "date": "2026-04-10", "published_at": "2026-04-10T00:56:17Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Timharford.com", "title": "The usefulness of useless knowledge", "description": "Of honey bees, long shots, and the usefulness of useless knowledge...", "url": "https://timharford.com/2026/04/the-usefulness-of-useless-knowledge/", "date": "2026-04-09", "published_at": "2026-04-09T16:59:00Z", "sentiment": { "label": "negative", "score": -0.296, "confidence": 0.3 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Global Noninvasive Cancer Diagnostics Market to Reach $165.2 Billion by 2030 as Liquid Biopsy, AI-Enabled Screening and Multi-Cancer Detection Tests Transform Oncology", "description": "Market growth is driven by rising cancer prevalence, demand for minimally invasive procedures, and advances in precision diagnostics....", "url": "https://www.globenewswire.com/news-release/2026/04/09/3271135/0/en/Global-Noninvasive-Cancer-Diagnostics-Market-to-Reach-165-2-Billion-by-2030-as-Liquid-Biopsy-AI-Enabled-Screening-and-Multi-Cancer-Detection-Tests-Transform-Oncology.html", "date": "2026-04-09", "published_at": "2026-04-09T14:12:00Z", "sentiment": { "label": "negative", "score": -0.823, "confidence": 0.82 } }, { "source": "news", "source_name": "Streetartutopia.com", "title": "Made You Dream (12 Photos)", "description": "Some street art changes a wall. These pieces change the whole feeling of a place. From a rainbow staircase in Sardinia to a glowing betta fish in Portugal, a giant box opening across a real building, and a shark scene hiding under concrete, every work here tu…", "url": "https://streetartutopia.com/2026/04/09/street-art-that-change-the-feeling-of-a-place/", "date": "2026-04-09", "published_at": "2026-04-09T14:01:00Z", "sentiment": { "label": "positive", "score": 0.077, "confidence": 0.08 } }, { "source": "news", "source_name": "Plos.org", "title": "Cell-free RNA reveals host and microbial correlates of broadly neutralizing antibody development against HIV", "description": "Author summary A subset of people living with HIV develop broadly neutralizing antibodies (bNAbs), a phenomenon that remains poorly understood but relevant to vaccine development. We applied combined cell-free RNA and DNA sequencing to 42 longitudinal plasma …", "url": "https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1014066", "date": "2026-04-09", "published_at": "2026-04-09T14:00:00Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Thechronicle.com.gh", "title": "Citi FM/Channel One TV Extend Easter Orphan Project to Prisons", "description": "Management and staff of Citi FM and Channel One TV, through the Citi FM Foundation, have expanded their annual Easter Orphan Project to include prisons, orphanages and rehabilitation centres across the country, reaching a broader segment of vulnerable populat…", "url": "https://thechronicle.com.gh/citi-fm-channel-one-tv-extend-easter-orphan-project-to-prisons/", "date": "2026-04-09", "published_at": "2026-04-09T11:31:11Z", "sentiment": { "label": "positive", "score": 0.153, "confidence": 0.15 } }, { "source": "news", "source_name": "Pypi.org", "title": "product-dl added to PyPI", "description": "Youtube-DL but for product pages.", "url": "https://pypi.org/project/product-dl/", "date": "2026-04-09", "published_at": "2026-04-09T04:10:38Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Github.com", "title": "Show HN: CCG – Block merges until devs prove they read their own diff", "description": "Article URL: https://github.com/islandbytesio/commit_comprehension_gate\nComments URL: https://news.ycombinator.com/item?id=47698781\nPoints: 2\n# Comments: 0", "url": "https://github.com/islandbytesio/commit_comprehension_gate", "date": "2026-04-09", "published_at": "2026-04-09T02:49:36Z", "sentiment": { "label": "negative", "score": -0.44, "confidence": 0.44 } }, { "source": "news", "source_name": "Github.com", "title": "Show HN: Infer – Pipe friendly Agent Harness with one tool: Bash", "description": "I wanted a lightweight harness to run local models. By constraining it to a single tool (Bash) the focus can be on building the programs around it and making the program itself as close to using a Unix program as possible so that it is also easily fit into an…", "url": "https://github.com/turlockmike/infer", "date": "2026-04-08", "published_at": "2026-04-08T23:55:21Z", "sentiment": { "label": "positive", "score": 0.796, "confidence": 0.8 } }, { "source": "news", "source_name": "Gibil.dev", "title": "Show HN: Give Claude Code disposable servers to work on tasks in parallel", "description": "Just launched. Looking for first users and feedback!\n\nComments URL: https://news.ycombinator.com/item?id=47696013\nPoints: 2\n# Comments: 0", "url": "https://www.gibil.dev/", "date": "2026-04-08", "published_at": "2026-04-08T20:44:28Z", "sentiment": { "label": "positive", "score": 0.2, "confidence": 0.2 } }, { "source": "news", "source_name": "Github.com", "title": "Show HN: BAREmail ʕ·ᴥ·ʔ – minimalist Gmail client for bad WiFi", "description": "I've been frustrated one too many times by terrible airplane wifi and not being able to load Gmail or Superhuman when all I want to do is get a few simple text-only emails out the door.These clients have become pretty bloated with the assumption you've always…", "url": "https://github.com/matt-virgo/baremail", "date": "2026-04-08", "published_at": "2026-04-08T14:44:23Z", "sentiment": { "label": "negative", "score": -0.758, "confidence": 0.76 } }, { "source": "news", "source_name": "BleepingComputer", "title": "Is a $30,000 GPU Good at Password Cracking?", "description": "A $30,000 AI GPU doesn't outperform consumer GPUs at password cracking. Specops explains why attackers don't need exotic hardware to break weak passwords. [...]", "url": "https://www.bleepingcomputer.com/news/security/is-a-30-000-gpu-good-at-password-cracking/", "date": "2026-04-08", "published_at": "2026-04-08T14:00:10Z", "sentiment": { "label": "negative", "score": -0.372, "confidence": 0.37 } }, { "source": "news", "source_name": "Linuxgizmos.com", "title": "Sony AS-DT1 LiDAR Depth Sensor Now Available in Compact 29 mm Form Factor", "description": "Sony Electronics has announced availability of the AS-DT1 LiDAR depth sensor, unveiled last year. It is described as one of the smallest LiDAR sensors in its class and is designed for integration into size- and weight-constrained systems such as mobile robots…", "url": "https://linuxgizmos.com/sony-as-dt1-lidar-depth-sensor-now-available-in-compact-29-mm-form-factor/", "date": "2026-04-08", "published_at": "2026-04-08T04:31:30Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Thechronicle.com.gh", "title": "Introduce Modernised E-Levy To Rake In Revenue -CPS", "description": "A strong case has been made for the reintroduction of a redesigned Electronic Transfer Levy (E-Levy), as Economists and tax experts warn that Ghana’s decision to abolish key taxes risks widening fiscal deficits and undermining long-term development. The propo…", "url": "https://thechronicle.com.gh/introduce-modernised-e-levy-to-rake-in-revenue-cps/", "date": "2026-04-08", "published_at": "2026-04-08T00:45:01Z", "sentiment": { "label": "negative", "score": -0.178, "confidence": 0.18 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Rapid Growth in Cell-Free Tumor DNA Detection Market: Forecast to Reach $5.64 Billion by 2030 as Advancements in Personalized Medicine Propel Expansion", "description": "Dublin, April 07, 2026 (GLOBE NEWSWIRE) -- The \"Cell Free Tumor Deoxyribonucleic Acid (DNA) Detection Market Report 2026\" has been added to ResearchAndMarkets.com's offering.", "url": "https://www.globenewswire.com/news-release/2026/04/07/3269503/28124/en/Rapid-Growth-in-Cell-Free-Tumor-DNA-Detection-Market-Forecast-to-Reach-5-64-Billion-by-2030-as-Advancements-in-Personalized-Medicine-Propel-Expansion.html", "date": "2026-04-07", "published_at": "2026-04-07T16:23:00Z", "sentiment": { "label": "positive", "score": 0.202, "confidence": 0.2 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Molecular Tumor Board Solutions Market Outlook 2026-2030 & 2035 with Competitor Market Share Data", "description": "Key growth factors include expanding precision oncology programs, genomic data integration, and cloud deployment in healthcare, with strong potential in Asia-Pacific Key growth factors include expanding precision oncology programs, genomic data integration, a…", "url": "https://www.globenewswire.com/news-release/2026/04/07/3269500/28124/en/Molecular-Tumor-Board-Solutions-Market-Outlook-2026-2030-2035-with-Competitor-Market-Share-Data.html", "date": "2026-04-07", "published_at": "2026-04-07T16:15:00Z", "sentiment": { "label": "positive", "score": 0.832, "confidence": 0.83 } }, { "source": "news", "source_name": "NYLON", "title": "Katseye On Coachella, Conflict & 'Showing Up For Each Other'", "description": "Days before Manon's hiatus, Katseye opened up about their \"Gnarly\" rise to fame, conflict resolution, their \"iconic\" Coachella plans, and new single \"Pinky Up.\"", "url": "https://www.nylon.com/entertainment/katseye-coachella-cover-story-interview", "date": "2026-04-07", "published_at": "2026-04-07T12:22:35Z", "sentiment": { "label": "negative", "score": -0.178, "confidence": 0.18 } }, { "source": "news", "source_name": "Pypi.org", "title": "gh-ai-runner 0.1.5", "description": "Serverless AI inference via GitHub Actions — no server required", "url": "https://pypi.org/project/gh-ai-runner/0.1.5/", "date": "2026-04-07", "published_at": "2026-04-07T04:20:51Z", "sentiment": { "label": "negative", "score": -0.296, "confidence": 0.3 } }, { "source": "news", "source_name": "Thechronicle.com.gh", "title": "Deliver Value For Money Or Face Sanctions – GETFund Boss Warns Contractors", "description": "The Administrator of the Ghana Education Trust Fund (GETFund), Paul Adjei, has reaffirmed the Fund’s commitment to enforcing strict quality standards in the execution of education infrastructure projects, warning contractors to deliver value for money or face…", "url": "https://thechronicle.com.gh/deliver-value-for-money-or-face-sanctions-getfund-boss-warns-contractors/", "date": "2026-04-07", "published_at": "2026-04-07T01:09:57Z", "sentiment": { "label": "positive", "score": 0.784, "confidence": 0.78 } }, { "source": "news", "source_name": "Pypi.org", "title": "skills-forge added to PyPI", "description": "A clean-architecture toolkit for crafting, linting, packing, and sharing Claude Code skills", "url": "https://pypi.org/project/skills-forge/", "date": "2026-04-06", "published_at": "2026-04-06T20:51:34Z", "sentiment": { "label": "positive", "score": 0.421, "confidence": 0.42 } }, { "source": "news", "source_name": "Pypi.org", "title": "gh-ai-runner 0.1.3", "description": "Serverless AI inference via GitHub Actions — no server required", "url": "https://pypi.org/project/gh-ai-runner/", "date": "2026-04-06", "published_at": "2026-04-06T20:17:03Z", "sentiment": { "label": "negative", "score": -0.296, "confidence": 0.3 } }, { "source": "news", "source_name": "Github.com", "title": "Show HN: Orchestrating AI into reviewable PRs you can reason about", "description": "Article URL: https://github.com/ninthwave-sh/ninthwave\nComments URL: https://news.ycombinator.com/item?id=47662921\nPoints: 2\n# Comments: 0", "url": "https://github.com/ninthwave-sh/ninthwave", "date": "2026-04-06", "published_at": "2026-04-06T16:20:13Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Github.com", "title": "Show HN: A Open Source Claude Code setup to publish Research papers 10x faster", "description": "Software engineering productivity increased dramatically with AI, but research workflows still feel slow and fragmented.So I built R-stack, a Claude code setup tailor made for ML and other computational Research.You just give it your idea and R-stack will:\n• …", "url": "https://github.com/sunnnybala/Rstack", "date": "2026-04-06", "published_at": "2026-04-06T15:09:22Z", "sentiment": { "label": "positive", "score": 0.141, "confidence": 0.14 } }, { "source": "news", "source_name": "Plos.org", "title": "Role of the C-terminal modules of Klebsiella phage KP32 receptor-binding protein gp38 in protein and phage functionality", "description": "Author summary Phages are viruses that attack bacteria, and they are being studied as possible alternatives to antibiotics, which are losing their effectiveness. But one big question remains: how do phages know which bacteria to infect? In our work, we looked…", "url": "https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1014106", "date": "2026-04-06", "published_at": "2026-04-06T14:00:00Z", "sentiment": { "label": "negative", "score": -0.431, "confidence": 0.43 } }, { "source": "news", "source_name": "Pypi.org", "title": "geoafrica added to PyPI", "description": "A unified geospatial data SDK for Africa and the world — open data, one package.", "url": "https://pypi.org/project/geoafrica/", "date": "2026-04-06", "published_at": "2026-04-06T13:53:24Z", "sentiment": { "label": "positive", "score": 0.382, "confidence": 0.38 } }, { "source": "news", "source_name": "Internet", "title": "How LiteLLM Turned Developer Machines Into Credential Vaults for Attackers", "description": "The most active piece of enterprise infrastructure in the company is the developer workstation. That laptop is where credentials are created, tested, cached, copied, and reused across services, bots, build tools, and now local AI agents.\nIn March 2026, the Te…", "url": "https://thehackernews.com/2026/04/how-litellm-turned-developer-machines.html", "date": "2026-04-06", "published_at": "2026-04-06T11:45:00Z", "sentiment": { "label": "positive", "score": 0.075, "confidence": 0.08 } }, { "source": "news", "source_name": "Wattsupwiththat.com", "title": "Demonstrating the Reverse Greenhouse Effect in the Laboratory – PART2", "description": "Measured gas emissions show increased infrared radiation and localized cooling effects, offering experimental observations relevant to ongoing debates over greenhouse processes.", "url": "https://wattsupwiththat.com/2026/04/06/demonstrating-the-reverse-greenhouse-effect-in-the-laboratory-part2/", "date": "2026-04-06", "published_at": "2026-04-06T09:00:00Z", "sentiment": { "label": "positive", "score": 0.273, "confidence": 0.27 } }, { "source": "news", "source_name": "Pypi.org", "title": "gh-llm 0.1.13", "description": " CLI tooling for LLM-first GitHub reading and review workflows.", "url": "https://pypi.org/project/gh-llm/0.1.13/", "date": "2026-04-06", "published_at": "2026-04-06T06:55:59Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Pypi.org", "title": "mdarena added to PyPI", "description": "Benchmark your CLAUDE.md against your own PRs", "url": "https://pypi.org/project/mdarena/", "date": "2026-04-05", "published_at": "2026-04-05T23:26:16Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Github.com", "title": "Show HN: jmux – tmux-based development environment for humans and coding agents", "description": "I've been a tmux user for years. When I started running 5-10 Claude Code sessions in parallel, I tried the tools that are out there: Conductor, cmux, the GUI orchestrators. None of them felt right. They either wanted me to leave tmux entirely for a 100MB+ Ele…", "url": "https://github.com/jarredkenny/jmux", "date": "2026-04-05", "published_at": "2026-04-05T15:10:14Z", "sentiment": { "label": "negative", "score": -0.052, "confidence": 0.05 } }, { "source": "news", "source_name": "Wattsupwiththat.com", "title": "Demonstrating the Reverse Greenhouse Effect in the Laboratory – PART1", "description": "Laboratory experiments explore infrared emission of greenhouse gases under normal pressure, raising questions about atmospheric heat transfer and radiative assumptions.", "url": "https://wattsupwiththat.com/2026/04/05/demonstrating-the-reverse-greenhouse-effect-in-the-laboratory/", "date": "2026-04-05", "published_at": "2026-04-05T09:00:00Z", "sentiment": { "label": "negative", "score": -0.296, "confidence": 0.3 } }, { "source": "news", "source_name": "Pypi.org", "title": "torchtext2 added to PyPI", "description": "Add your description here", "url": "https://pypi.org/project/torchtext2/", "date": "2026-04-04", "published_at": "2026-04-04T10:48:30Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Github.com", "title": "Show HN: RemembrallMCP – code dependency graph for agents and memory", "description": "After watching Claude Code and Codex keep running Explore in my codebase over and over, I started to think that there must be a better way. RemembrallMCP is my attempt to fix this.RemembrallMCP gives agents two things most memory tools don't:1. Persistent Mem…", "url": "https://github.com/cdnsteve/remembrallmcp", "date": "2026-04-04", "published_at": "2026-04-04T06:39:29Z", "sentiment": { "label": "positive", "score": 0.44, "confidence": 0.44 } }, { "source": "news", "source_name": "Pypi.org", "title": "parol-pygen 0.1.0", "description": "Python parser generator/runtime consuming parol export JSON", "url": "https://pypi.org/project/parol-pygen/", "date": "2026-04-03", "published_at": "2026-04-03T14:25:06Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Github.com", "title": "Show HN: Zumly – a library for building zooming user interfaces", "description": "Article URL: https://github.com/zumerlab/zumly\nComments URL: https://news.ycombinator.com/item?id=47625640\nPoints: 1\n# Comments: 1", "url": "https://github.com/zumerlab/zumly", "date": "2026-04-03", "published_at": "2026-04-03T11:53:42Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Thechronicle.com.gh", "title": "Three Remanded Over Alleged Land cruiser Theft in Tarkwa", "description": "The Circuit Court in Tarkwa, presided over by Her Honour Bernice Mensimah Akoh, has remanded three persons into custody for their alleged involvement in a vehicle theft syndicate operating in the area. The accused persons are Kojo Amponsah, also known as “Kam…", "url": "https://thechronicle.com.gh/three-remanded-over-alleged-land-cruiser-theft-in-tarkwa/", "date": "2026-04-03", "published_at": "2026-04-03T11:24:01Z", "sentiment": { "label": "positive", "score": 0.361, "confidence": 0.36 } }, { "source": "news", "source_name": "Thechronicle.com.gh", "title": "Dispatch Rider Jailed 10 Years for Robbing Diplomat’s Secretary", "description": "The Circuit Court at Dansoman has sentenced a 24-year-old dispatch rider to 10 years’ imprisonment for robbing the Secretary to the Namibian High Commissioner in Ghana. The convict, Daniel Asiuebi, pleaded guilty simpliciter to two counts of robbery and causi…", "url": "https://thechronicle.com.gh/dispatch-rider-jailed-10-years-for-robbing-diplomats-secretary/", "date": "2026-04-03", "published_at": "2026-04-03T11:21:38Z", "sentiment": { "label": "negative", "score": -0.727, "confidence": 0.73 } }, { "source": "news", "source_name": "Seclists.org", "title": "Re: [vim-security] Vim tabpanel modeline escape affects Vim", "description": "Posted by Salvatore Bonaccorso on Apr 03Hi,\n\nAccording to https://www.cve.org/CVERecord?id=CVE-2026-34714 the\nassigner is MITRE CNA itself.\n\nRegards,\nSalvatore", "url": "https://seclists.org/oss-sec/2026/q2/20", "date": "2026-04-03", "published_at": "2026-04-03T09:51:48Z", "sentiment": { "label": "positive", "score": 0.178, "confidence": 0.18 } }, { "source": "news", "source_name": "Bulinews.com", "title": "Former Germany coach Joachim Löw linked with World Cup job", "description": "Joachim Löw, who won the World Cup with Germany in 2014, is said to be close to a return to coaching.Citing “multiple sources,” Ghanasoccernet.com reports that Löw is close to being appointed Gh...", "url": "https://bulinews.com/former-germany-coach-joachim-low-linked-world-cup-job", "date": "2026-04-03", "published_at": "2026-04-03T09:08:00Z", "sentiment": { "label": "positive", "score": 0.572, "confidence": 0.57 } }, { "source": "news", "source_name": "Pypi.org", "title": "release-cli added to PyPI", "description": "AI-assisted CLI release manager powered by Backboard", "url": "https://pypi.org/project/release-cli/", "date": "2026-04-03", "published_at": "2026-04-03T00:11:17Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Pypi.org", "title": "memex-oss added to PyPI", "description": "Institutional knowledge extraction for engineering teams", "url": "https://pypi.org/project/memex-oss/", "date": "2026-04-02", "published_at": "2026-04-02T16:25:08Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "TechRadar", "title": "5 popular OpenClaw integrations that will level up your productivity", "description": "A practical look at five of the most popular OpenClaw integrations, covering messaging, productivity, developer tools, and smart home control.", "url": "https://www.techradar.com/pro/5-popular-openclaw-integrations-that-will-level-up-your-productivity", "date": "2026-04-02", "published_at": "2026-04-02T14:43:31Z", "sentiment": { "label": "positive", "score": 0.822, "confidence": 0.82 } }, { "source": "news", "source_name": "Plos.org", "title": "Football (Soccer) refereeing and cardiovascular health: A scoping review", "description": "Background Physical and psychological stress can precipitate Acute Coronary Syndrome (ACS) events. Football (soccer) is a popular sport globally, with referees covering significant distances, often at high-intensity during a match, and facing potentially inte…", "url": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0346360", "date": "2026-04-02", "published_at": "2026-04-02T14:00:00Z", "sentiment": { "label": "positive", "score": 0.202, "confidence": 0.2 } }, { "source": "news", "source_name": "Plos.org", "title": "Effects of a native avian predator (weka; Gallirallus australis) and colony density on breeding success of a burrow-nesting seabird (tītī; Ardenna grisea)", "description": "As island ecosystems are restored, native predators are recovering and re-establishing interactions with their prey. However, compared with widely-publicised impacts of invasive predators, little is known about the dynamics and stability of native predator-pr…", "url": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0346357", "date": "2026-04-02", "published_at": "2026-04-02T14:00:00Z", "sentiment": { "label": "positive", "score": 0.802, "confidence": 0.8 } }, { "source": "news", "source_name": "Plos.org", "title": "Availability and affordability of essential medicines for non-communicable disease management in primary healthcare: Evidence from three municipalities in Ghana", "description": "Background Non-communicable diseases (NCDs) cause 74% of global deaths, disproportionately affecting LMICs like Ghana. Chronic treatment remains hindered by medicine shortages and high costs, consuming over 50% of the minimum wage incomes. Despite Ghana’s NCD…", "url": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0346140", "date": "2026-04-02", "published_at": "2026-04-02T14:00:00Z", "sentiment": { "label": "positive", "score": 0.226, "confidence": 0.23 } }, { "source": "news", "source_name": "YEN.COM.GH", "title": "Former Health Minister Dr Bernard Okoe-Boye Summoned Before PAC", "description": "The former Health Minister, Dr Bernard Okoe-Boye, has been summoned by PAC over GH¢20 million in mobilisation funds for the Parliamentary Hospital.", "url": "https://yen.com.gh/politics/302253-former-health-minister-dr-bernard-okoe-boye-summoned-pac/", "date": "2026-04-02", "published_at": "2026-04-02T12:36:49Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Github.com", "title": "Show HN: Clawd Pets – 90 animated SVG pets, pure CSS, no dependencies", "description": "Article URL: https://github.com/abderrahimghazali/clawd-pet\nComments URL: https://news.ycombinator.com/item?id=47613069\nPoints: 2\n# Comments: 0", "url": "https://github.com/abderrahimghazali/clawd-pet", "date": "2026-04-02", "published_at": "2026-04-02T11:39:38Z", "sentiment": { "label": "negative", "score": -0.296, "confidence": 0.3 } }, { "source": "news", "source_name": "Seclists.org", "title": "Re: [vim-security] Vim tabpanel modeline escape affects Vim", "description": "Posted by Christian Brabandt on Apr 02Tianyu Chen schrieb am Donnerstag, den 02. April 2026:\n\nYes, but Github did not assign it. Someone else did and GH did barely \nnotify me of this already existing CVE.\n\nThanks,\nChristian", "url": "https://seclists.org/oss-sec/2026/q2/8", "date": "2026-04-02", "published_at": "2026-04-02T11:24:50Z", "sentiment": { "label": "positive", "score": 0.723, "confidence": 0.72 } }, { "source": "news", "source_name": "Thechronicle.com.gh", "title": "Sachet Water Prices to Rise From Monday as Polymer Crisis Bites", "description": "Ghanaians who rely on sachet water — the majority of the country’s drinking water consumers — will dig deeper into their pockets from Monday, April 6, 2026, after the National Association of Sachet and Packaged Water Producers (NASPAWAP) announced an upward r…", "url": "https://thechronicle.com.gh/sachet-water-prices-to-rise-from-monday-as-polymer-crisis-bites/", "date": "2026-04-02", "published_at": "2026-04-02T09:25:20Z", "sentiment": { "label": "negative", "score": -0.625, "confidence": 0.62 } }, { "source": "news", "source_name": "Pypi.org", "title": "gh-audit 0.2.1", "description": "GitHub audit, governance, and inventory for organizations", "url": "https://pypi.org/project/gh-audit/0.2.1/", "date": "2026-04-02", "published_at": "2026-04-02T08:02:49Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Thechronicle.com.gh", "title": "PAC Invites Two Public Officials Over GH¢8.2m Toilet Contracts", "description": "A GH¢8.2 million ‘Toilet-for-All’ contract scandal has erupted at the Public Accounts Committee (PAC), after government officials admitted they could not produce key documents backing the transactions, claiming the records had been transferred to archives. Th…", "url": "https://thechronicle.com.gh/pac-invites-two-public-officials-over-gh¢8-2m-toilet-contracts/", "date": "2026-04-02", "published_at": "2026-04-02T06:33:45Z", "sentiment": { "label": "negative", "score": -0.34, "confidence": 0.34 } }, { "source": "news", "source_name": "Pypi.org", "title": "acp-gh 1.6.0", "description": "Automatic Commit Pusher (acp) - CLI tool to create GitHub PRs from staged changes in a single command", "url": "https://pypi.org/project/acp-gh/1.6.0/", "date": "2026-04-02", "published_at": "2026-04-02T04:30:35Z", "sentiment": { "label": "positive", "score": 0.511, "confidence": 0.51 } }, { "source": "news", "source_name": "Github.com", "title": "Show HN: MinimumReleaseAge-style protection for Agent Skills", "description": "Article URL: https://github.com/skill-mill/agent-skill-porter\nComments URL: https://news.ycombinator.com/item?id=47604187\nPoints: 1\n# Comments: 1", "url": "https://github.com/skill-mill/agent-skill-porter", "date": "2026-04-01", "published_at": "2026-04-01T17:52:26Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Pypi.org", "title": "gh-audit 0.2.0", "description": "GitHub audit, governance, and inventory for organizations", "url": "https://pypi.org/project/gh-audit/0.2.0/", "date": "2026-04-01", "published_at": "2026-04-01T13:32:49Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Pypi.org", "title": "gh-unanswered 0.3.0", "description": "Find GitHub issues where you were @mentioned but haven't replied since", "url": "https://pypi.org/project/gh-unanswered/0.3.0/", "date": "2026-04-01", "published_at": "2026-04-01T10:11:23Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Aura Reports Updated Mineral Reserves and Mineral Resources For The Year-Ended 2025, Highlighting year of Significant Growth in Mineral Reserve and Resource Portfolio", "description": "Aura Reports Updated Mineral Reserves and Mineral Resources For The Year-Ended 2025, Highlighting year of Significant Growth in Mineral Reserve and Resourc", "url": "https://www.globenewswire.com/news-release/2026/04/01/3266406/0/en/Aura-Reports-Updated-Mineral-Reserves-and-Mineral-Resources-For-The-Year-Ended-2025-Highlighting-year-of-Significant-Growth-in-Mineral-Reserve-and-Resource-Portfolio.html", "date": "2026-04-01", "published_at": "2026-04-01T10:05:00Z", "sentiment": { "label": "positive", "score": 0.778, "confidence": 0.78 } }, { "source": "news", "source_name": "Pypi.org", "title": "gh-unanswered 0.2.0", "description": "Find GitHub issues where you were @mentioned but haven't replied since", "url": "https://pypi.org/project/gh-unanswered/0.2.0/", "date": "2026-04-01", "published_at": "2026-04-01T10:00:45Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Pypi.org", "title": "gh-unanswered added to PyPI", "description": "Find GitHub issues where you were @mentioned but haven't replied since", "url": "https://pypi.org/project/gh-unanswered/", "date": "2026-04-01", "published_at": "2026-04-01T09:54:56Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Pypi.org", "title": "gh-unanswered 0.1.0", "description": "Find GitHub issues where you were @mentioned but haven't replied since", "url": "https://pypi.org/project/gh-unanswered/0.1.0/", "date": "2026-04-01", "published_at": "2026-04-01T09:54:56Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Github.com", "title": "Show HN: Crossmind-CLI – CLI for X, Reddit, HN API with compact JSON output", "description": "A CLI for fetching data from social platforms (X, Reddit, HN, GitHub, LinkedIn, Product Hunt, etc.) with compressed JSON output. Built because raw GraphQL responses from X are ~3,900 tokens for 10 tweets — this gets it down to ~666 tokens.Features:\n- 15+ plat…", "url": "https://github.com/cross-mind/crossmind-cli", "date": "2026-04-01", "published_at": "2026-04-01T09:43:51Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Thechronicle.com.gh", "title": "Politics Halts Rice, Maize Distribution –Agric Ministry Tells PAC", "description": "Proceedings of the Public Accounts Committee (PAC) of Parliament have revealed that political interference disrupted the execution of a major government grain distribution programme, preventing a contracted logistics firm from carrying out its mandate. Offici…", "url": "https://thechronicle.com.gh/politics-halts-rice-maize-distribution-agric-ministry-tells-pac/", "date": "2026-04-01", "published_at": "2026-04-01T02:07:17Z", "sentiment": { "label": "neutral", "score": -0.026, "confidence": 0.03 } }, { "source": "news", "source_name": "Thechronicle.com.gh", "title": "Nsein chief gives Lower Axim counter three-month ultimatum to vacate his land", "description": "A festering chieftaincy dispute between two paramount stools in Western Region has escalated sharply, raising fears of violence if urgent intervention is not secured. At the centre of the impasse are the Paramount Chief of Nsein, Awulae Agyefi Kwame, and the …", "url": "https://thechronicle.com.gh/nsein-chief-gives-lower-axim-counter-three-month-ultimatum-to-vacate-his-land/", "date": "2026-04-01", "published_at": "2026-04-01T01:00:53Z", "sentiment": { "label": "negative", "score": -0.905, "confidence": 0.91 } }, { "source": "news", "source_name": "Github.com", "title": "Show HN: Initialize an AI Harness with Forge CLI", "description": "AI agent pipeline scaffolding CLI — detects stack, renders CLAUDE.md, agents, hooks, pipeline scripts, and compliance addons - samahlstrom/forge-cli", "url": "https://github.com/samahlstrom/forge-cli", "date": "2026-03-31", "published_at": "2026-03-31T23:24:44Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Github.com", "title": "Show HN: King Louie a local multi-machine AI assistant", "description": "Article URL: https://github.com/the-banana-tool/king-louie\nComments URL: https://news.ycombinator.com/item?id=47593640\nPoints: 1\n# Comments: 0", "url": "https://github.com/the-banana-tool/king-louie", "date": "2026-03-31", "published_at": "2026-03-31T21:23:33Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Anime News Network", "title": "Hosana Tanaka's Megami no Ko Manga Ends With 3rd Volume", "description": "Manga ended serialization in November, final volume shipped on Monday", "url": "https://www.animenewsnetwork.com/news/2026-03-31/hosana-tanaka-megami-no-ko-manga-ends-with-3rd-volume/.235991", "date": "2026-03-31", "published_at": "2026-03-31T21:00:00Z", "sentiment": { "label": "negative", "score": -0.296, "confidence": 0.3 } }, { "source": "news", "source_name": "Pypi.org", "title": "deepdoc 0.1.1", "description": "Auto-generate beautiful docs from any codebase", "url": "https://pypi.org/project/deepdoc/", "date": "2026-03-31", "published_at": "2026-03-31T19:59:23Z", "sentiment": { "label": "positive", "score": 0.599, "confidence": 0.6 } }, { "source": "news", "source_name": "Pypi.org", "title": "gh-audit 0.1.3", "description": "GitHub audit, governance, and inventory for organizations", "url": "https://pypi.org/project/gh-audit/0.1.3/", "date": "2026-03-31", "published_at": "2026-03-31T19:51:32Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Pypi.org", "title": "gh-audit 0.1.2", "description": "GitHub audit, governance, and inventory for organizations", "url": "https://pypi.org/project/gh-audit/0.1.2/", "date": "2026-03-31", "published_at": "2026-03-31T19:09:09Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Pypi.org", "title": "gh-audit added to PyPI", "description": "GitHub audit, governance, and inventory for organizations", "url": "https://pypi.org/project/gh-audit/", "date": "2026-03-31", "published_at": "2026-03-31T19:09:05Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Yahoo Entertainment", "title": "Guardant Health (GH) and Verana Health Announces New Partnership", "description": "", "url": "https://consent.yahoo.com/v2/collectConsent?sessionId=1_cc-session_eddc6600-b47b-4adb-920c-3402b82dbd0c", "date": "2026-03-31", "published_at": "2026-03-31T15:06:18Z", "sentiment": { "label": "positive", "score": 0.2, "confidence": 0.2 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Precision Medicine Software Market Outlook 2026-2030 & 2035 - Philips, Palantir Technologies, and Tempus Labs Lead the $2.82 Billion Industry", "description": "Growth is fueled by advancements in genomic technologies, rising precision oncology, and focus on interoperable healthcare systems Growth is fueled by advancements in genomic technologies, rising precision oncology, and focus on interoperable healthcare syste…", "url": "https://www.globenewswire.com/news-release/2026/03/31/3265764/28124/en/Precision-Medicine-Software-Market-Outlook-2026-2030-2035-Philips-Palantir-Technologies-and-Tempus-Labs-Lead-the-2-82-Billion-Industry.html", "date": "2026-03-31", "published_at": "2026-03-31T15:04:00Z", "sentiment": { "label": "positive", "score": 0.637, "confidence": 0.64 } }, { "source": "news", "source_name": "Plos.org", "title": "Biobanking of gynecologic cancer biospecimens: Development, quality control, and translational applications", "description": "Introduction This study presents a nationwide infrastructure for the collection and utilization of gynecologic cancer biospecimens, established through the Korea Biobank Project. We comprehensively describe the biobanking strategy, quality control protocols, …", "url": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0345861", "date": "2026-03-31", "published_at": "2026-03-31T14:00:00Z", "sentiment": { "label": "negative", "score": -0.869, "confidence": 0.87 } }, { "source": "news", "source_name": "Plos.org", "title": "The adapt-to-nutrient NRPS-like secondary metabolite gene cluster facilitates Verticillium dahliae adaptation to different nutrient environments", "description": "Author summary Verticillium dahliae is an economically significant phytopathogen that is widely distributed. The fungus adjusts and adapts its survival strategy according to the surrounding environment. Transcriptome data revealed that the core biosynthetic g…", "url": "https://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1011930", "date": "2026-03-31", "published_at": "2026-03-31T14:00:00Z", "sentiment": { "label": "positive", "score": 0.202, "confidence": 0.2 } }, { "source": "news", "source_name": "Plos.org", "title": "Determination of factors that allow cryogenic nanoscopy with high power illumination without devitrification", "description": "Cryogenic fluorescence nanoscopy, also known as super-resolution fluorescence light microscopy, has been demonstrated to be useful to close the resolution gap in cryogenic correlative light and electron microscopy (CLEM). Importantly, under cryogenic conditio…", "url": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0344631", "date": "2026-03-31", "published_at": "2026-03-31T14:00:00Z", "sentiment": { "label": "positive", "score": 0.832, "confidence": 0.83 } }, { "source": "news", "source_name": "Plos.org", "title": "New Histone H4 variant and H2B variant Exhibits distinct genomic distributions, chromatin affinities, and dynamics throughout life and cell cycle of Trypanosoma cruzi", "description": "Author summary Chromatin is composed of a group of proteins called histones that are involved in compacting DNA and thereby affecting many DNA-associated mechanisms, such as replication and transcription. Histone variants share distinct primary sequences from…", "url": "https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1013310", "date": "2026-03-31", "published_at": "2026-03-31T14:00:00Z", "sentiment": { "label": "positive", "score": 0.511, "confidence": 0.51 } }, { "source": "news", "source_name": "Github.com", "title": "Show HN: \"Have your LLM talk to my LLM\"", "description": "Article URL: https://github.com/dvelton/rendezvous\nComments URL: https://news.ycombinator.com/item?id=47587094\nPoints: 1\n# Comments: 1", "url": "https://github.com/dvelton/rendezvous", "date": "2026-03-31", "published_at": "2026-03-31T13:30:31Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Pypi.org", "title": "json-object-mapper added to PyPI", "description": "Attribute-style access wrapper for JSON-like data with dot-path set/delete and safe defaults", "url": "https://pypi.org/project/json-object-mapper/", "date": "2026-03-31", "published_at": "2026-03-31T10:09:56Z", "sentiment": { "label": "positive", "score": 0.44, "confidence": 0.44 } }, { "source": "news", "source_name": "Github.com", "title": "Show HN: HolyCode – OpenCode in Docker. Use your Claude subscription. 30 tools", "description": "HolyCode is a Docker image that wraps OpenCode (https://opencode.ai), an AI coding agent with a web UI. It ships with 30+ dev tools pre-installed, a headless Chromium/Xvfb/Playwright stack, s6-overlay for process supervision, and UID/GID remapping for correct…", "url": "https://github.com/CoderLuii/HolyCode", "date": "2026-03-31", "published_at": "2026-03-31T08:29:46Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Thechronicle.com.gh", "title": "Heath Goldfields Has Brought Renewed Hope To Prestea-Bogoso -Group", "description": "Hope has been rekindled in the Prestea-Bogoso enclave following the rapid revival of mining operations by Heath Goldfields, with residents and stakeholders calling on government to safeguard the company’s growing investment. At a press conference held yesterd…", "url": "https://thechronicle.com.gh/heath-goldfields-has-brought-renewed-hope-to-prestea-bogoso-group/", "date": "2026-03-31", "published_at": "2026-03-31T08:04:42Z", "sentiment": { "label": "positive", "score": 0.844, "confidence": 0.84 } }, { "source": "news", "source_name": "Thechronicle.com.gh", "title": "Tarkwa Court Remands Two Students Over Supermarket Break-In and Theft", "description": "The Circuit Court in Tarkwa has remanded two young men, including a student of Takoradi Technical University, into custody for allegedly stealing cash and goods from a local supermarket. The accused, Kingsford Quarshie, also known as “Cash Money,” 21, a miner…", "url": "https://thechronicle.com.gh/tarkwa-court-remands-two-students-over-supermarket-break-in-and-theft/", "date": "2026-03-31", "published_at": "2026-03-31T07:56:13Z", "sentiment": { "label": "negative", "score": -0.71, "confidence": 0.71 } }, { "source": "news", "source_name": "Droppedasbaby.com", "title": "Accidentally created my first fork bomb with Claude Code", "description": "Accidentally created my first fork bomb with Claude Code, bricked my computer overnight, and somehow built useful tools along the way.", "url": "https://www.droppedasbaby.com/posts/2602-01/", "date": "2026-03-31", "published_at": "2026-03-31T07:40:18Z", "sentiment": { "label": "negative", "score": -0.649, "confidence": 0.65 } }, { "source": "news", "source_name": "Github.com", "title": "Show HN: Claudebase: Sync your Claude Code env across machines via GitHub", "description": "Article URL: https://github.com/rohithzr/claudebase\nComments URL: https://news.ycombinator.com/item?id=47583664\nPoints: 1\n# Comments: 0", "url": "https://github.com/rohithzr/claudebase", "date": "2026-03-31", "published_at": "2026-03-31T06:53:23Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Pypi.org", "title": "deathstar-ai added to PyPI", "description": "Secure AWS-hosted remote AI coding workstation with a provider-agnostic local CLI.", "url": "https://pypi.org/project/deathstar-ai/", "date": "2026-03-31", "published_at": "2026-03-31T06:15:04Z", "sentiment": { "label": "positive", "score": 0.34, "confidence": 0.34 } }, { "source": "news", "source_name": "ComingSoon.net", "title": "Sofia Mattsson’s New Soap Casting Revealed After General Hospital Exit", "description": "Sofia Mattsson is making a dramatic move after her seven-year stint as Sasha Gilmore on General Hospital. After exiting the ABC drama, Mattsson has been busy preparing for her next chapter. With her extensive experience in daytime drama, the Swedish-born actr…", "url": "https://www.comingsoon.net/tv/news/2114104-sofia-mattsson-cast-days-of-our-lives-general-hospital", "date": "2026-03-31", "published_at": "2026-03-31T05:56:58Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Github.com", "title": "Agent-Reach - Give your AI agent eyes to see the entire internet", "description": "Give your AI agent eyes to see the entire internet. Read & search Twitter, Reddit, YouTube, GitHub, Bilibili, XiaoHongShu — one CLI, zero API fees. - Panniantong/Agent-Reach", "url": "https://github.com/Panniantong/Agent-Reach", "date": "2026-03-31", "published_at": "2026-03-31T05:47:01Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Deadline", "title": "Sofia Mattsson Joins ‘Days Of Our Lives’ Following ‘General Hospital’ Departure", "description": "Salem is getting a new resident in Sofia Mattsson. The former General Hospital actress will be jumping networks to NBC’s Days of our Lives, the soap announced in a joint post shared to Instagram. “Sofia Mattsson is making her way to Salem early next year! ⏳…", "url": "http://deadline.com/2026/03/sofia-mattsson-days-of-our-lives-cast-addition-1236769635/", "date": "2026-03-31", "published_at": "2026-03-31T02:48:43Z", "sentiment": { "label": "positive", "score": 0.4, "confidence": 0.4 } }, { "source": "news", "source_name": "Pypi.org", "title": "aimio-py added to PyPI", "description": "Python bindings for the Numerics88 AimIO C++ library", "url": "https://pypi.org/project/aimio-py/", "date": "2026-03-31", "published_at": "2026-03-31T02:47:14Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Pypi.org", "title": "ez-stack 0.2.11", "description": "Stacked PRs for GitHub — agent-first CLI for parallel development", "url": "https://pypi.org/project/ez-stack/", "date": "2026-03-31", "published_at": "2026-03-31T00:17:47Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Pypi.org", "title": "acp-gh 1.5.0", "description": "Automatic Commit Pusher (acp) - CLI tool to create GitHub PRs from staged changes in a single command", "url": "https://pypi.org/project/acp-gh/1.5.0/", "date": "2026-03-30", "published_at": "2026-03-30T23:12:09Z", "sentiment": { "label": "positive", "score": 0.511, "confidence": 0.51 } }, { "source": "news", "source_name": "Thechronicle.com.gh", "title": "Police Gun Down Suspected Armed Robber on Atebubu–Ejura Highway", "description": "The Ghana Police Service has allegedly shot dead a suspected notorious armed robber, Osman Amadu, popularly known as “Manu,” during an intelligence-led operation along the Atebubu–Ejura highway. According to police reports, the incident occurred on March 18, …", "url": "https://thechronicle.com.gh/police-gun-down-suspected-armed-robber-on-atebubu-ejura-highway/", "date": "2026-03-30", "published_at": "2026-03-30T17:22:17Z", "sentiment": { "label": "negative", "score": -0.95, "confidence": 0.95 } }, { "source": "news", "source_name": "Pypi.org", "title": "gh-bin 2.89.0", "description": "A thin wrapper to distribute https://github.com/cli/cli via pip.", "url": "https://pypi.org/project/gh-bin/2.89.0/", "date": "2026-03-30", "published_at": "2026-03-30T16:16:36Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Pypi.org", "title": "wizardenv added to PyPI", "description": "A powerful AI SDK with vision, speech, and multi-backend support", "url": "https://pypi.org/project/wizardenv/", "date": "2026-03-30", "published_at": "2026-03-30T15:03:36Z", "sentiment": { "label": "positive", "score": 0.758, "confidence": 0.76 } }, { "source": "news", "source_name": "Stephenjude.me", "title": "How to Setup PIE for PHP Extensions on macOS", "description": "Pie is the official PHP extension installer and the replacement for PECL. In this article, I will show you how to get Pie up and running on your local machine.", "url": "https://stephenjude.me/articles/how-to-setup-pie-for-php-extensions-on-macos?utm_source=laravelnews&utm_medium=link&utm_campaign=laravelnews", "date": "2026-03-30", "published_at": "2026-03-30T13:00:00Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Thechronicle.com.gh", "title": "Donors cheer up SHS Arts students for decorating Asokwa Interchange", "description": "Individuals and institutions have trooped to the Asokwa Interchange with food, drinks and cash donations to support Visual Arts students from Senior High Schools who are engaged in decorating the Asokwa Interchange. The project forms part of the novelle Ashan…", "url": "https://thechronicle.com.gh/donors-cheer-up-shs-arts-students-for-decorating-asokwa-interchange/", "date": "2026-03-30", "published_at": "2026-03-30T12:05:55Z", "sentiment": { "label": "positive", "score": 0.827, "confidence": 0.83 } }, { "source": "news", "source_name": "Thechronicle.com.gh", "title": "Filmmakers Summit Held in Kumasi to boost Kumawood Industry", "description": "A Filmmakers Summit has been held in Kumasi to revitalise the Ghanaian film industry as part of the Ashanti Festival 2026. Secretary to the Kumawood Board of Directors, Emmanuel Opoku Anane, said the summit is designed to enhance the industry’s vibrancy and s…", "url": "https://thechronicle.com.gh/filmmakers-summit-held-in-kumasi-to-boost-kumawood-industry/", "date": "2026-03-30", "published_at": "2026-03-30T12:01:36Z", "sentiment": { "label": "positive", "score": 0.71, "confidence": 0.71 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Gene Panel Market Size to Projected Reach USD 17.18 Billion by 2035, Driven by Precision Medicine Adoption – SNS Insider", "description": "Rising demand for early disease detection, expanding oncology applications, and rapid advancements in next-generation sequencing technologies propel market growth at 16.69% CAGR. Rising demand for early disease detection, expanding oncology applications, and …", "url": "https://www.globenewswire.com/news-release/2026/03/30/3264508/0/en/Gene-Panel-Market-Size-to-Projected-Reach-USD-17-18-Billion-by-2035-Driven-by-Precision-Medicine-Adoption-SNS-Insider.html", "date": "2026-03-30", "published_at": "2026-03-30T11:12:00Z", "sentiment": { "label": "positive", "score": 0.178, "confidence": 0.18 } }, { "source": "pubmed", "pmid": "41963611", "title": "Outcomes of patients with or without DNA repair pathway alterations: the MD Anderson IMPACT2 study.", "authors": "Venturini J et al.", "journal": "NPJ precision oncology", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41963611/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41962211", "title": "Implementing a molecular prescreening strategy for tumors without public NGS access in a cancer center network: Results from the PREICO project.", "authors": "Sàbat P et al.", "journal": "European journal of cancer (Oxford, England : 1990)", "date": "2026 Apr 4", "url": "https://pubmed.ncbi.nlm.nih.gov/41962211/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41957135", "title": "Impact of tumor location on the efficacy of concurrent chemoradiotherapy for locally advanced non-small cell lung cancer.", "authors": "Ozawa Y et al.", "journal": "British journal of cancer", "date": "2026 Apr 9", "url": "https://pubmed.ncbi.nlm.nih.gov/41957135/", "sentiment": { "label": "negative", "score": -0.718, "confidence": 0.72 } }, { "source": "pubmed", "pmid": "41956545", "title": "Phase 1b study of ABBV-368, tilsotolimod, budigalimab, and nab-paclitaxel in patients with recurrent/metastatic head and neck squamous cell carcinoma.", "authors": "Daste A et al.", "journal": "Journal for immunotherapy of cancer", "date": "2026 Apr 9", "url": "https://pubmed.ncbi.nlm.nih.gov/41956545/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41956543", "title": "HosTIL territory: mapping the landscape of toxicity in TIL therapy.", "authors": "Woodford R et al.", "journal": "Journal for immunotherapy of cancer", "date": "2026 Apr 9", "url": "https://pubmed.ncbi.nlm.nih.gov/41956543/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41951768", "title": "High-throughput screening identifies NT-1 that synergizes with MRTX1133 against acquired resistant KRAS(G12D) colorectal cancer.", "authors": "Thielen N et al.", "journal": "NPJ precision oncology", "date": "2026 Apr 8", "url": "https://pubmed.ncbi.nlm.nih.gov/41951768/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41951735", "title": "Multiomics and deep learning dissect regulatory syntax in human development.", "authors": "Liu BB et al.", "journal": "Nature", "date": "2026 Apr 8", "url": "https://pubmed.ncbi.nlm.nih.gov/41951735/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41950928", "title": "Antibody-drug conjugates in breast cancer: Progress and future directions.", "authors": "Bili Newman A et al.", "journal": "Cell reports. Medicine", "date": "2026 Apr 7", "url": "https://pubmed.ncbi.nlm.nih.gov/41950928/", "sentiment": { "label": "negative", "score": -0.382, "confidence": 0.38 } }, { "source": "pubmed", "pmid": "41945065", "title": "Effectiveness of amivantamab compared with real-world therapies in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations post platinum-based chemotherapy.", "authors": "Wu JY et al.", "journal": "Journal of the Formosan Medical Association = Taiwan yi zhi", "date": "2026 Apr 6", "url": "https://pubmed.ncbi.nlm.nih.gov/41945065/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41938080", "title": "Clinical Concordance of Pan Lung Cancer PCR Panel Covering 167 Actionable Variants Across 11 Genes and Other Validated Assays in the LC-SCRUM-Asia Registry.", "authors": "Matsumoto S et al.", "journal": "JTO clinical and research reports", "date": "2026-04-11", "url": "https://pubmed.ncbi.nlm.nih.gov/41938080/", "sentiment": { "label": "negative", "score": -0.542, "confidence": 0.54 } }, { "source": "pubmed", "pmid": "41935073", "title": "IL1R1 blockade augments CD40 agonist mediated immunity in pancreatic cancer.", "authors": "Boda AR et al.", "journal": "Scientific reports", "date": "2026 Apr 4", "url": "https://pubmed.ncbi.nlm.nih.gov/41935073/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41934464", "title": "Definitive Radiotherapy to the Primary Tumor in Stage IV NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer Advanced Radiation Technology Subcommittee.", "authors": "McMahon RA et al.", "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer", "date": "2026 Apr 3", "url": "https://pubmed.ncbi.nlm.nih.gov/41934464/", "sentiment": { "label": "negative", "score": -0.718, "confidence": 0.72 } }, { "source": "pubmed", "pmid": "41933595", "title": "Safety profile of KRAS G12C inhibitors combined with thoracic radiation therapy.", "authors": "Miller DG et al.", "journal": "Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology", "date": "2026 Mar 3", "url": "https://pubmed.ncbi.nlm.nih.gov/41933595/", "sentiment": { "label": "positive", "score": 0.202, "confidence": 0.2 } }, { "source": "pubmed", "pmid": "41933194", "title": "Treatment monitoring by biomarker analysis in a Phase I dose-expansion study of AZD2811 for relapsed/refractory small-cell lung cancer.", "authors": "Johnson ML et al.", "journal": "British journal of cancer", "date": "2026 Apr 3", "url": "https://pubmed.ncbi.nlm.nih.gov/41933194/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41931739", "title": "Longitudinal, Retrospective Use of a Circulating Tumor DNA Methylation Signature Successfully Captures Small Cell Evolution in a Patient With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer.", "authors": "Patil T et al.", "journal": "JCO precision oncology", "date": "2026-04-11", "url": "https://pubmed.ncbi.nlm.nih.gov/41931739/", "sentiment": { "label": "negative", "score": -0.586, "confidence": 0.59 } }, { "source": "pubmed", "pmid": "41931218", "title": "Sequential Use of Trastuzumab Deruxtecan and Sacituzumab Govitecan in Patients with Breast Cancer: A Pharmacological Approach to Support the Clinical Rationale.", "authors": "Del Re M et al.", "journal": "Drugs", "date": "2026 Apr 3", "url": "https://pubmed.ncbi.nlm.nih.gov/41931218/", "sentiment": { "label": "negative", "score": -0.402, "confidence": 0.4 } }, { "source": "pubmed", "pmid": "41925922", "title": "Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trial.", "authors": "Hörner M et al.", "journal": "Breast cancer research and treatment", "date": "2026 Apr 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41925922/", "sentiment": { "label": "negative", "score": -0.527, "confidence": 0.53 } }, { "source": "pubmed", "pmid": "41924551", "title": "Key Considerations for Targeting KRAS in Pancreatic Cancer: Potential Impact on the Treatment Paradigm.", "authors": "Eslinger C et al.", "journal": "Drug design, development and therapy", "date": "2026-04-11", "url": "https://pubmed.ncbi.nlm.nih.gov/41924551/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41922144", "title": "Gene testing and prognosis in post-operative recurrent non-small-cell lung cancer: subgroup analyses of WJOG15421L.", "authors": "Matsubara T et al.", "journal": "ESMO open", "date": "2026 Mar 3", "url": "https://pubmed.ncbi.nlm.nih.gov/41922144/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41922143", "title": "Comparative efficacy of zanubrutinib plus obinutuzumab versus last prior treatment in relapsed/refractory follicular lymphoma: growth modulation index analysis from the ROSEWOOD study.", "authors": "Trotman J et al.", "journal": "ESMO open", "date": "2026 Mar 3", "url": "https://pubmed.ncbi.nlm.nih.gov/41922143/", "sentiment": { "label": "positive", "score": 0.382, "confidence": 0.38 } }, { "source": "pubmed", "pmid": "41917211", "title": "Phase 1 study of ceralasertib, an ATR kinase inhibitor, in combination with durvalumab in patients with recurrent or metastatic NSCLC or HNSCC.", "authors": "Lopez JS et al.", "journal": "British journal of cancer", "date": "2026 Mar 3", "url": "https://pubmed.ncbi.nlm.nih.gov/41917211/", "sentiment": { "label": "negative", "score": -0.077, "confidence": 0.08 } }, { "source": "pubmed", "pmid": "41917040", "title": "Loss of luminal lineage drives resistance to next-generation ERα antagonists in pretreated ER(+) HER2(-) locally-advanced or metastatic breast cancer.", "authors": "Liang J et al.", "journal": "Nature communications", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41917040/", "sentiment": { "label": "negative", "score": -1.0, "confidence": 1.0 } }, { "source": "pubmed", "pmid": "41910021", "title": "A plain language summary of the updated results from the PHAROS study: the combination of encorafenib plus binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer.", "authors": "Johnson ML et al.", "journal": "Future oncology (London, England)", "date": "2026-04-11", "url": "https://pubmed.ncbi.nlm.nih.gov/41910021/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41903996", "title": "Utility of Circulating Tumor DNA-Based Liquid Biopsies in Patients with Cancer Receiving Immunotherapy.", "authors": "Teixeira MF et al.", "journal": "Surgical oncology clinics of North America", "date": "2026-04-11", "url": "https://pubmed.ncbi.nlm.nih.gov/41903996/", "sentiment": { "label": "negative", "score": -0.791, "confidence": 0.79 } }, { "source": "pubmed", "pmid": "41903301", "title": "Phase Ia/Ib trial of the safety and efficacy of mobocertinib in combination with T-DM1 for patients with HER2-mutant solid tumors (WJOG16022M).", "authors": "Kanemura H et al.", "journal": "European journal of cancer (Oxford, England : 1990)", "date": "2026 May 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41903301/", "sentiment": { "label": "positive", "score": 0.527, "confidence": 0.53 } }, { "source": "pubmed", "pmid": "41899521", "title": "Association Between Patient-Reported Outcomes and Overall Survival in Patients with Advanced NSCLC Treated with First-Line Cemiplimab-Based Therapy.", "authors": "Gandara DR et al.", "journal": "Cancers", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41899521/", "sentiment": { "label": "positive", "score": 0.25, "confidence": 0.25 } }, { "source": "pubmed", "pmid": "41898529", "title": "Genome-Wide CRISPR Screens Identify ABCG2-Mediated Drug Resistance to the Threonine Tyrosine Kinase (TTK) Inhibitor CFI-402257 in Breast Cancer.", "authors": "Thu KL et al.", "journal": "International journal of molecular sciences", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41898529/", "sentiment": { "label": "negative", "score": -0.691, "confidence": 0.69 } }, { "source": "pubmed", "pmid": "41896648", "title": "Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial.", "authors": "Cho BC et al.", "journal": "Nature medicine", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41896648/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41895789", "title": "Comparison of tissue acquisition techniques for Next-Generation Sequencing of non-small cell lung cancer (NSCLC).", "authors": "Bhamani A et al.", "journal": "BMJ open respiratory research", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41895789/", "sentiment": { "label": "negative", "score": -0.46, "confidence": 0.46 } }, { "source": "pubmed", "pmid": "41895314", "title": "Consensus definition of stage III non-small-cell lung cancer technical resectability to standardise inclusion criteria for clinical trials: a multisocietal EORTC-Lung Cancer Group collaboration.", "authors": "Dingemans AC et al.", "journal": "The Lancet. Respiratory medicine", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41895314/", "sentiment": { "label": "negative", "score": -0.869, "confidence": 0.87 } }, { "source": "pubmed", "pmid": "41892875", "title": "Baseline tumor burden and outcomes in patients with rare cancers treated with immunotherapy (Southwest Oncology Group trial S1609).", "authors": "Swiecicki PL et al.", "journal": "Cancer", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41892875/", "sentiment": { "label": "negative", "score": -0.67, "confidence": 0.67 } }, { "source": "pubmed", "pmid": "41883872", "title": "Molecular complete response to the RIN protocol (regorafenib, ipilimumab, and nivolumab) in a patient with advanced recurrent metastatic mismatch repair proficient/microsatellite stable (pMMR/MSS) rectal cancer.", "authors": "Qadri F et al.", "journal": "Therapeutic advances in medical oncology", "date": "2026-04-11", "url": "https://pubmed.ncbi.nlm.nih.gov/41883872/", "sentiment": { "label": "negative", "score": -0.296, "confidence": 0.3 } }, { "source": "pubmed", "pmid": "41882405", "title": "Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial.", "authors": "Park W et al.", "journal": "Nature medicine", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41882405/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41880871", "title": "Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST).", "authors": "Kito Y et al.", "journal": "European journal of cancer (Oxford, England : 1990)", "date": "2026 May 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41880871/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41876649", "title": "AI-based chest X-ray prioritization in the lung cancer diagnostic pathway: the LungIMPACT randomized controlled trial.", "authors": "Woznitza N et al.", "journal": "Nature medicine", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41876649/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41874648", "title": "Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV).", "authors": "Mollica V et al.", "journal": "Cancer immunology, immunotherapy : CII", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41874648/", "sentiment": { "label": "positive", "score": 0.25, "confidence": 0.25 } }, { "source": "pubmed", "pmid": "41872602", "title": "Implementation of the NHS England Lung Cancer Screening Programme over 5 years.", "authors": "Lee RW et al.", "journal": "Nature medicine", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41872602/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41871874", "title": "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0.", "authors": "McKay RR et al.", "journal": "Journal for immunotherapy of cancer", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41871874/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41870735", "title": "Efficacy and safety of trastuzumab biosimilar CT-P6 plus SOX or CapeOX in HER2-positive advanced gastric cancer: a multicenter phase II KSCC-TROX study.", "authors": "Oki E et al.", "journal": "Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41870735/", "sentiment": { "label": "negative", "score": -0.153, "confidence": 0.15 } }, { "source": "pubmed", "pmid": "41866411", "title": "Efficacy and safety of peptide radionuclide therapy with (177)Lu-DOTATATE in Japanese patients with advanced neuroendocrine neoplasm: a multicenter retrospective study (JON2203-N).", "authors": "Okamoto K et al.", "journal": "Journal of gastroenterology", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41866411/", "sentiment": { "label": "positive", "score": 0.586, "confidence": 0.59 } }, { "source": "pubmed", "pmid": "41864749", "title": "Survival outcome of VATS compared with open lobectomy for lung cancer: an individual patient data meta-analysis of randomised trials.", "authors": "Harris RA et al.", "journal": "Lancet (London, England)", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41864749/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41861751", "title": "Sacituzumab govitecan in patients with metastatic breast cancer: pooled safety analysis of data from patients in North America, Europe, and Asia.", "authors": "Rugo HS et al.", "journal": "ESMO open", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41861751/", "sentiment": { "label": "negative", "score": -0.382, "confidence": 0.38 } }, { "source": "pubmed", "pmid": "41861516", "title": "Multidisciplinary international expert consensus recommendations on tissue acquisition in non-small cell lung cancer.", "authors": "Lee P et al.", "journal": "EBioMedicine", "date": "2026-04-11", "url": "https://pubmed.ncbi.nlm.nih.gov/41861516/", "sentiment": { "label": "negative", "score": -0.46, "confidence": 0.46 } }, { "source": "pubmed", "pmid": "41860053", "title": "AGMT mCRC Registry Third-Line and Beyond: a multicentric real-world platform with integrated imaging and biosample database for later-line metastatic colorectal cancer.", "authors": "Huemer F et al.", "journal": "Future oncology (London, England)", "date": "2026-04-11", "url": "https://pubmed.ncbi.nlm.nih.gov/41860053/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41858873", "title": "Tolerance and Resistance to Targeted Therapy in NSCLC: Emerging Concepts and Strategies.", "authors": "Sanchez-Cespedes M et al.", "journal": "JTO clinical and research reports", "date": "2026-04-11", "url": "https://pubmed.ncbi.nlm.nih.gov/41858873/", "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "pubmed", "pmid": "41851476", "title": "Real-world analysis of androgen receptor inhibitors in US patients with nonmetastatic castration-resistant prostate cancer: DEAR-EXT study.", "authors": "Shore ND et al.", "journal": "Prostate cancer and prostatic diseases", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41851476/", "sentiment": { "label": "negative", "score": -0.751, "confidence": 0.75 } }, { "source": "pubmed", "pmid": "41849281", "title": "Implementing a successful patient navigation program for follow-up colonoscopy: Lessons from the PRECISE study.", "authors": "Thompson JH et al.", "journal": "PloS one", "date": "2026-04-11", "url": "https://pubmed.ncbi.nlm.nih.gov/41849281/", "sentiment": { "label": "positive", "score": 0.586, "confidence": 0.59 } }, { "source": "pubmed", "pmid": "41847154", "title": "Clinical Outcomes and Safety of Concurrent Chemoradiotherapy in EGFR-Mutant Unresectable Stage III NSCLC.", "authors": "Takamori S et al.", "journal": "JTO clinical and research reports", "date": "2026-04-11", "url": "https://pubmed.ncbi.nlm.nih.gov/41847154/", "sentiment": { "label": "positive", "score": 0.421, "confidence": 0.42 } }, { "source": "pubmed", "pmid": "41843267", "title": "SEOM-TTCC clinical guidelines for the treatment of head and neck cancer (2025).", "authors": "Arrazubi V et al.", "journal": "Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41843267/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41840238", "title": "First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial.", "authors": "Shitara K et al.", "journal": "Nature medicine", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41840238/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } } ] } }